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ABSTRACT 
Aims 
The aims of this thesis work were to answer the following questions. Paper I: How prevalent is 
testing and retesting with prostate-specific antigen (PSA)?; Paper II: Is a genetic score based on 
single-nucleotide polymorphisms (SNPs) informative regarding the risk of prostate cancer 
(PCa) in men with low PSA?; Paper III: Are the commercially available tests Prostate Health 
Index (PHI) and the four-kallikrein panel comparable in aiding biopsy decisions?; Paper IV: Do 
commonly used medications affect PSA and the risk of PCa? 
Methods 
In Paper I and Paper IV, the population-based PSA cohort STHLM0 was used together with 
registry-based data. Paper I described limited-duration point prevalence of testing and survival 
analysis describing retesting with PSA. Paper IV determined differences in PCa risk and PSA 
level among men using aspirin, statin, metformin or no medication. Paper II included 172 men 
with PSA at 1‒3ng/ml. Participants were invited according to their genetic score and underwent 
prostate biopsy. Risk of prostate cancer was assessed using logistic regression. Paper III 
included 531 men who had undergone a first prostate biopsy. Predictive models were compared 
using receiver-operating characteristics (ROC/AUC) and calculation of biopsies that could be 
avoided.  
Results 
Paper I: During a 9-year study period, 46%, 68%, and 77% of men without previous PCa and 
aged 50–59 years, 60–69 years, and 70–79 years, respectively, had a PSA test. The 
probability of retesting with PSA was PSA- and age-dependent, with a 26-month cumulative 
incidence of 0.34 if the first PSA value was < 1 ng/ml. Paper II: PCa was diagnosed in 47 of 
172 men with PSA levels of 1‒3ng/ml (27%), with Gleason sum of ≥ 7 in 10 of them (5.8%). 
There was an increase in the odds ratio of 1.60 with increasing genetic risk score. The 
absolute difference in risk of positive biopsy was 19 percentage points, comparing the high 
and low genetic risk groups (37% vs. 18%). Paper III: The four-kallikrein panel showed 
AUCs of 69.0 when predicting PCa of any grade and 71.8 when predicting high-grade cancer 
(Gleason score ≥ 7). Similar values were found for PHI (70.4 and 71.1, respectively). Both 
models had higher AUCs than a base model with PSA value and age. Using a 10% predicted 
risk of high-grade PCa by the four-kallikrein panel or PHI = 39 as cutoff for biopsy saved 
29% of the biopsies performed, at a cost of delayed diagnosis for 10% of the men with high-
grade cancer. Paper IV: There were no significant associations between aspirin or any anti-
diabetic medication and the risk of PCa. Men using any statin had an increased risk of both 
high-grade PCa and PCa overall (OR = 1.25; OR = 1.16). Compared to men without the 
medication, the level of the first PSA was lower in men using aspirin, statin, metformin, or 
insulin. 
Conclusions 
Although screening for PCa is not recommended in Sweden, PSA testing in Stockholm County 
was high in men aged over 50 years. A risk score based on SNPs predicts biopsy outcome in 
previously unbiopsied men with PSA levels of 1–3 ng/ml. Furthermore, we found that two 
blood tests, the PHI and the four-kallikrein panel, performed similarly in predicting prostate 
biopsy outcome. Introduction of such risk stratification tools could increase the proportion of 
men being classified in line with their true risk of PCa. We found no protective effect of aspirin, 
statins, or antidiabetics in terms of overall risk of prostate cancer or high-grade cancer. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Prostatacancer är den vanligaste cancer-relaterade dödsorsaken hos svenska män och 
cirka 1 av 20 män avlider av sjukdomen. En ansenlig andel av män med icke avancerad 
prostatacancer påverkas dock inte av sjukdomen under sin livstid. Efter att testning med 
blodprovet Prostata-Specifikt Antigen (PSA) inleddes har förekomsten av känd 
prostatacancer ökat kraftigt, och dödligheten har minskat på senare år. Nuvarande 
utbredning av testning med PSA är ofullständigt känd. 
 
PSA-testning kan leda till minskad risk att dö av prostatacancer, då man kan 
diagnosticera och kan behandla sjukdomen i ett tidigt skede. Å andra sidan har PSA-
provet begränsad precision att identifiera män som kommer utveckla allvarlig sjukdom 
och man riskerar att diagnosticera många män med ofarlig sjukdom om organiserade 
screening-program införs. Därför är det prioriterat att utveckla och validera bättre 
testverktyg för att detektera potentiellt allvarlig prostatacancer. Särskilt bland män med 
hög risk för sjukdom är det rimligt att också utvärdera värdet av förebyggande 
medicinering. Flera mediciner har föreslagits som associerade med risken att utveckla 
prostatacancer, men ingen har hittills visat tillräckligt värde för att användas.  
 
I den här avhandlingen presenteras fyra delarbeten med målsättningen att (i) kartlägga 
hur PSA-testning används idag, (ii) validera hur väl nya test-verktyg presterar i att 
förutspå om en man har prostatacancer och (iii) att studera om medicinerna acetyl-
salicylsyra, statiner eller metformin har en skyddande effekt på risken att utveckla 
prostatacancer. 
 
I delarbete I utnyttjades den befolkningsbaserade databasen STHLM0 som täcker alla 
män som genomgått PSA-testning i Stockholms län sedan 2011. Vi använde register-
samkörningar med befolkningsregister och flera kvalitetsregister för att uppskatta både 
förekomsten av PSA-testning och återkommande testning. Vi fann att det var vanligt att 
genomgå PSA-test och att testning var vanlig även bland grupper som sannolikt inte 
gagnas av det. Cirka 6 av 10 män mellan 50 och 80 år genomgick testning med PSA de 
senaste 9 åren. Återkommande testning var vanlig även hos män med låga PSA-värden 
som har låg risk att utveckla allvarlig sjukdom. Vidare fann vi att det var vanligt att 
genomgå PSA-test även bland äldre män som har mycket lite att vinna på sådan 
testning. 
 
En mans uppsättning av genetiska nukleotidpolymorfismer (SNP) är associerad med 
hans risk att utveckla prostatacancer. Denna kännedom är begränsad till män som 
utreds för prostatacancer i dagens vård, trots att vi vet att det förekommer 
prostatacancer även hos symtomfria män med låga PSA-värden. Målet med delarbete 
II var att studera sambandet mellan uppsättningen SNP hos män med låga PSA-värden 
och deras risk att ha prostatacancer. Vi genomförde en klinisk studie där vi bjöd in män 
till vävnadsprov av prostata. Vi fann att en mans uppsättning av SNP är associerat med 
risken att ha prostatacancer bland män med låga PSA-värden. Analys av SNP-
uppsättning utgör en möjlighet att identifiera män med hög risk för prostatacancer som 
inte utreds enligt klinisk praxis idag. 
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Flera verktyg har föreslagits för att underlätta bedömningen av en mans risk att ha 
prostatacancer. Två sådana är de kommersiellt tillgängliga blodproven Prostate Health 
Index (PHI, Beckman Coulter Inc.) och four-kallikrein panel (4KScore, OPKO Health 
Inc.). I delarbete III jämförde vi hur väl dessa test presterade i en svensk grupp av män 
som genomgått utredning med vävnadsprover av prostata (STHLM2). Vi fann att PHI 
och 4KScore presterade likvärdigt och kunde bespara cirka tre av tio män 
vävnadsprovtagning enligt klinisk praxis till kostnaden av att missa ett av tio hög-
gradiga cancerfall. Både PHI och 4KScore identifierade prostatacancer bättre än en 
modell med PSA och ålder. 
 
För att säkerställa nyttan med en medicinsk intervention såsom screening eller 
erbjudande av förebyggande medicinering krävs ofta stora och kostsamma 
randomiserade prövningar. Epidemiologiska studier erbjuder ofta lägre värderad, men 
lättare tillgänglig kunskap och kan vägleda om stora prövningar ska inledas. Delarbete 
IV är en epidemiologisk studie där vi använde samma stora grupp män som i delarbete 
I. Vi identifierade män som genomgått PSA-provtagning och sedan män som 
genomgått vävnadsprovtagning av prostata. Vi samkörde studiegruppen mot bland 
annat läkemedelsregistret (Socialstyrelsen) för att utvärdera om medicinering med 
acetylsalicylsyra, stationer eller anti-diabetika såsom metformin var associerad med 
risken att finna prostatacancer vid vävnadsprovtagning. Vi fann inga tecken till någon 
skyddande effekt av acetylsalicylsyra, stationer eller metformin för risken att utveckla 
prostatacancer och planerar inte att ta initiativ till större prövningar för att studera 
förebyggande behandling med dessa mediciner. 
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PREFACE 
The ideas for this thesis spring from a few underlying facts that determine today’s 
prostate cancer care. First, prostate cancer is a common and sometimes lethal disease 
with great impact on individuals, healthcare, and society. The widespread use of the 
prostate-specific antigen (PSA) test has resulted in a situation marked by frequent 
unorganized testing of unknown proportions―aimed at early detection in order to 
reduce the risk of dying from prostate cancer. From this comes over-diagnosis, 
whereby men who would otherwise be unaffected by a relatively benign untreated 
prostate cancer run the risk of having unwanted side effects from invasive diagnostic 
procedures and treatments. 
 
In order to improve this situation, better tools for detection of prostate cancer are 
urgently needed. A number of tests have been suggested for this, but only a few are 
close to implementation in clinical care. Proper validation of such tools will be 
necessary before their widespread clinical introduction or incorporation in organized 
screening programs. 
 
In addition, apart from efficient diagnosis, it is important to discuss prevention of this 
common cancer, which causes about one in twenty deaths in men. Although far from 
clinical implementation, a few common, cheap, and well-characterized medications 
have shown promise in preventing prostate cancer, and these require further evaluation. 
 
In this thesis work, I have set out (1) to improve our knowledge of PSA testing 
behavior; (2) to validate the performance of biomarkers that are close to 
implementation, and (3) to investigate whether some suggested medications prevent 
prostate cancer. 
 
Paper I is a registry study exploring current PSA testing. Paper II is a clinical study 
evaluating the performance of a genetic score when predicting prostate cancer in men 
with low PSA values. Paper III compares the commercially available tests Prostate 
Health Index (PHI) and the four-kallikrein panel in predicting prostate cancer. Paper IV 
is a registry study exploring prevention of prostate cancer using aspirin, statin, and 
antidiabetics. 
 
 
Stockholm 2014-11-24 
 
 
 
Tobias Nordström  
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1 INTRODUCTION 
1.1 RELEVANCE OF STUDYING PROSTATE CANCER 
1.1.1 Incidence and mortality 
Prostate cancer is the second most common cancer in men, with an estimated 1.1 
million men being diagnosed worldwide in 2012 and 70% of the cases being identified 
in more developed regions. The incidence varies widely between regions, with the 
highest incidence in North America, Australia/New Zealand, and Europe [1]. In 
Sweden, it is the most common cancer in males with 8,985 new cases in 2012 and a 
slowly decreasing incidence trend since 2009 [2]. The mortality of prostate cancer 
varies less, and it has been estimated that prostate cancer accounts for 6.6% of male 
deaths worldwide with high age-standardized mortality rates in predominantly black 
populations, low in Asia, and intermediate in Europe and North America [1].  
 
After the introduction of PSA testing, the incidence of prostate cancer has increased 
substantially, especially in men with localized, low-grade disease. Simultaneously, 
mortality rates in some countries have decreased, possibly due to an increase in early 
treatment. On average, mortality rates have declined by approximately 3% per year 
2001-2010 in the USA where PSA testing was adopted early on, and a corresponding 
decrease in mortality has been seen in Sweden in later years [3]. 
 
Figure 1: Age-standardized incidence and mortality rates per 100,000 people in the USA and Sweden. 
Incidence scale on the left axis and mortality on the right. Age-adjustment according to the world 
population. Data from IARC, WHO. 
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1.2 DIAGNOSIS AND TREATMENT 
A comprehensive description of the diagnosis and treatment of prostate cancer is 
beyond the scope of this thesis, but can be found elsewhere [2,4]. However, it is worth 
making a few comments to put the work in context. 
 
1.2.1 Diagnosis  
Prostate cancer is most commonly diagnosed from prostate biopsies, a smaller fraction 
being diagnosed from fine-needle aspirations from the prostate, surgical specimens 
(e.g. TUR-P), or purely clinically. Prostate biopsies are recommended for men with an 
increased risk of prostate cancer, as judged by risk factors (e.g. age, family history, 
ethnicity, comorbidity), clinical findings (DRE, MRI, symptoms), and levels of 
biomarkers (e.g. tPSA, fPSA, SNPs, PHI, 4K, PCA3 etc.). In clinical practice, the level 
of PSA, age, and DRE findings often form the basis for estimating the risk of finding 
cancer on biopsy. Since the performance of the PSA test is limited (see 1.3.3.2) and the 
positive predictive value of a suspect palpatory finding (by DRE) is only 5‒30% in 
patients with low PSA (< 4ng/ml) [5], additional aids are needed for decision making. 
 
In prostate biopsy, 10‒12 biopsies are most often taken under ultrasound guidance and 
with local anesthesia after giving antibiotic prophylaxis (commonly 750 mg 
ciprofloxacin before the procedure). Ultrasound gives poor visualization of prostate 
tumors, which is why sampling is done systematically, focusing on the peripheral zone 
of the prostate, which is known to harbor most cancer lesions. If indicated, additional 
biopsies are taken from the transitional zone. When the results show benign findings, 
repeat biopsies are recommended in cases with rising tPSA, suspicious DRE findings, 
suspicious findings on first biopsy (prostatic intraepithelial neoplasia, atypical small 
acinar proliferation), or persisting clinical suspicion of prostate cancer.  
 
A variety of complications have been associated with prostate biopsies historically 
(hematospermia, 37%; hematuria, 14%; rectal bleeding, 2%; fever > 38.5oC, 1%) [4]. 
The infectious complications seem to increase, and the proportion of men with post-
biopsy infections due to antibiotic-resistant bacterial strains is indeed increasing. The 
proportion of men having a blood culture within 30 days after a prostate biopsy can be 
a crude approximation of the risk of severe post-biopsy infection. Using the STHLM0 
cohort (see Materials 3.1), our research group has retrieved data on virtually all men in 
Stockholm County undergoing prostate biopsy and their blood cultures. Unpublished 
data (Aly M.) show an increasing proportion of men undergoing a blood culture within 
30 days after biopsy and an increasing proportion of resistant strains found in those 
cultures. In brief, Stockholm men now appear to have more than a 2% risk of having a 
severe post-biopsy infection requiring blood culture, and one out of four blood cultures 
will show bacterial strains with signs of antibiotic resistance. The re-admission rate 
after prostate biopsy is 1‒3% depending on the healthcare system, and the proportion 
suffering from a febrile urinary tract infection is approximately 3% [6]. 
 
A biopsy result is reported including the Gleason score grading and the extent of 
malignant findings (mm cancer; % cancer in each core). The prognosis of prostate 
cancer varies according to cancer stage, grade, and PSA level. Thus, the primary 
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staging usually includes information on DRE, biopsy findings, and PSA. Radiology 
(MRI, bone scan, CT scan) can be used to help estimate stage. The 2009 TNM 
classification for prostate cancer states that T1 corresponds to a clinically inapparent 
tumor; T2 is a palpable tumor confined to the prostate (T2b: more than half the 
prostatic lobe; T2c: bilobar nodule); T3 is a tumor extending through the prostatic 
capsule; and T4 is a tumor invading other surrounding structures (not including the 
seminal vesicles; e.g. sphincter, rectum, levator muscles). N1 and M1 refer to nodal 
metastasis and distant metastasis, respectively, while N0/M0 means no such metastasis 
and Nx/Mx means lack of information. There are several risk stratification systems, of 
which a modified version of the D’Amico classification is recommended in Sweden 
[2,7]; see Table 1. 
 
Table 1: Classification of prostate cancer according to Swedish national guidelines [2]  
Risk Stage Grade PSA (ng/ml) Additional requirements 
Very low T1‒T2a Gleason ≤ 6 < 10 < 8 mm ca. in 8‒12 cores 
< 4 of 8‒12 cores ca. 
PSA density < 0.15/cm3 
Low T1‒T2a Gleason ≤ 6 < 10  
Intermediate T2b Gleason = 7 10‒19.9  
High T2c‒T3 Gleason > 7 or 
extensive Gleason 4 + 3 
≥ 20  
ca., cancer. 
 
 
1.2.2 Prostate cancer survival 
The number of men living with insignificant prostate tumors (i.e. tumors that will not 
affect the man if untreated) is high and age-dependent, as seen in autopsy studies and 
Table 2 [8].  
 
Table 2: Prevalence of prostate cancer in a US population without prostate cancer diagnosis as found in 
autopsies [8]. 
 < 49 years 50‒59 years 60‒69 years 70‒79 years 
PCa prevalence 1 % 23 % 35 % 46 % 
 
 
The risk of dying from the disease after a prostate cancer diagnosis varies widely with 
stage and grade. A Swedish study followed 223 men with localized prostate cancer that 
was not treated except for hormonal treatment after symptoms appeared [9]. At 15 
years of follow-up the prostate cancer-specific survival was 89% in men with Gleason 
3‒6 disease, 66% in men with Gleason 7, and 28% in men with Gleason 8‒10 tumors. 
Men with non-palpable (then T0, now classified as T1) and palpable disease (then T1‒
T2, now T2‒T3) had similar disease-specific survival at 15 years (80%), but after 25 
years of follow-up, the men with palpable disease were worse off than the men without 
palpable findings at diagnosis.  
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Converted into currently used risk grouping (using data from Rider and colleagues 
assessing more than 76,000 Swedish prostate cancer cases), survival when including 
treated men is shown in Table 3 for all ages. For a subset of men over 75 years of age, 
it is worth noting that even in regional metastatic disease, the cumulative risk of dying 
from prostate cancer was 39%―as compared to a 52% risk of dying from other causes 
within 10 years. 
 
Table 3: Percent cumulative prostate cancer-specific and other-cause mortality. From Rider et al. [10] 
 10-year cum. mortality (%) 15-year cum. mortality (%) 
Risk category Prostate cancer Other cause Prostate cancer Other cause 
All ages     
Low risk 4.5 29 8.9 50 
Intermediate risk 13 42 20 58 
High risk 29 45 36 55 
Regional metastatic 41 38 49 44 
Distant metastatic 66 25 70 28 
Age >75 years   
Low risk 7 56 10 78 
Intermediate risk 15 56 20 74 
High risk 29 53 33 63 
Regional metastatic 39 52 42 57 
Distant metastatic 63 32 64 35 
 
 
1.2.3 Treatment 
Treatment of prostate cancer can be summarized according to the three arms curative 
treatment (surgery, radiation), possible future curative treatment (active surveillance), 
or no curative treatment (hormonal therapy, chemotherapy, palliative radiation etc.).  
 
For men with low risk or very low risk of prostate cancer, active surveillance with 
repeated PSA and DRE assessments is often the recommended choice. In intermediate-
risk disease, curative treatment with radical prostatectomy or radiation therapy is 
recommended, provided there is an expected lifespan of more than 10 years. Results 
from the two trials SPCG-4 and PIVOT have been instrumental in guiding 
recommendations for both low-risk and intermediate risk disease [11,12]. In high-risk 
disease, curative treatment is also recommended in men with a shorter expected 
lifespan, but there is less consensus regarding which treatment modality should be 
preferred. The trial SPCG-7 showed that prostate cancer-specific mortality was about 
halved after 10 years in men with high-risk local prostate cancer treated with 
radiotherapy together with endocrine therapy, as compared to those treated with 
endocrine therapy alone (11.9% vs. 23.9%)[13]. However, a recent Swedish 
observational study supported the role of prostatectomy (as opposed to radiotherapy) in 
men with high-risk disease, and especially in young men [14]. There is a lack of trial-
based results comparing prostatectomy and radiation therapy in treatment of prostate 
cancer. Prostatectomy or radiation therapy is seldom used for men with distant 
metastases, widespread regional metastases, stage T4 or PSA > 100, and hormonal 
treatment is the first line of treatment instead [2].  
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1.3 BIOMARKERS IN EARLY DETECTION 
1.3.1 Classification of biomarkers  
According to a classification by the US National Institutes of Health (NIH), a 
biomarker is a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes, or pharmaceutical 
responses to a therapeutic intervention [15]. There are a number of situations where 
clinical decision making in cancer care can be aided by biomarkers. Six different types 
of biomarkers can be identified in prostate cancer, as outlined by Shariat et al. [16] 
and as shown in Table 4. 
 
 
Table 4: Conceptual types of biomarkers 
Biomarker function:  
Detection / Screening Used for evaluation of patients with or without risk factors for 
PCa. 
Diagnostic Helps classical histopathological characterization in 
determining the presence or absence of PCa. 
Prognostic Helps prediction of outcome in patients (e.g. risk of 
recurrence, progression), aiding individualized 
management. 
Predictive Used to predict treatment effectiveness or monitor 
effectiveness of treatment. Can aid choice of treatment.  
Surrogate endpoint Used to substitute for a clinical endpoint and/or to measure 
clinical benefit. Surrogates could replace traditional 
endpoints, such as mortality due to disease or the 
recurrence or relapse of disease. Biomarkers can reduce 
time factors and costs for phase-I and -II clinical trials by 
replacing clinical endpoints. 
 
 
A wide range of analyses have been proposed for prostate cancer detection. The focus 
of this thesis work has been on blood-based biomarkers for prostate cancer detection 
that are (i) in clinical use (PSA; Paper I); (ii) commercially available (PHI, 4K; Paper 
III), or (iii) close to clinical implementation (SNPs; Paper II). Brief descriptions of 
urinary markers and magnetic resonance imaging are presented, while both are 
interesting options in aiding biopsy decision. 
 
 
1.3.2 Evaluating the usefulness of biomarkers  
To be relevant for implementation, a biomarker must add value in clinical decision 
making. The performance of a biomarker can be described in the dimensions 
discrimination (the ability to predict prostate cancer outcome, for example) and 
calibration (if predicted risk corresponds to observed/real outcome), both of which are 
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necessary for clinical value. Discrimination can be described in terms of sensitivity 
(the proportion of cancer cases correctly identified by a positive test), specificity (the 
proportion of individuals with no cancer correctly identified by a negative test), 
positive predictive value (the proportion of diseased in individuals testing positive) 
and receiver-operating characteristics (ROC; plot of corresponding 
sensitivity/specificity by cutoff levels of the biomarker). The area under the ROC curve 
can be calculated as the area under the curve (AUC) and compared between 
biomarker combinations. Calibration is often illustrated by graphs correlating observed 
and estimated risks in a dataset. 
 
In order to increase the possibility of drawing relevant conclusions, guidelines on how 
to report tumor marker studies have been presented [17]. However, drawing 
conclusions on the clinical value of adding a biomarker to clinical practice is more 
complex, and existing studies are often lacking in this (at least partially) [18]. 
Addressing clinical usefulness can be done through several statistical methods, e.g. 
decision curve analysis, net reclassification improvement, and calculation of proportion 
of saved biopsies vs. missed cancers. 
 
 
1.3.3 Current practice 
1.3.3.1 Molecular forms of prostate-specific antigen (PSA) 
Currently, the only widely used biomarker in prostate cancer diagnostics is 
measurement of the concentration of prostate-specific antigen (kallikrein 3; PSA; 
tPSA). It was discovered in the 1970s, but was not used in clinical medicine for another 
decade [19-21]. In spite of being found at low concentrations in some malignant breast, 
adrenal, and renal tumors, for clinical purposes it is deemed prostate-specific [22]. The 
kallikrein-related peptidase family member PSA is a 33-kD protein secreted by the 
epithelial cells of the prostate. It is found in seminal plasma at one million-fold times 
higher concentration than in blood serum (mg/ml amounts rather than ng/ml amounts). 
Conditions affecting the prostate such as prostate carcinoma, inflammation, and benign 
enlargement all affect serum levels of PSA, possibly through disruption of the cellular 
architecture [23]. In serum, most PSA is in complexed form―bound to the carrier 
proteins α1-antichemotrypsin (ACT) and α2-macroglobulin (A2M).  
 
Five to 30% of the PSA that escapes to the blood is in unbound form (free PSA, fPSA). 
Free PSA exist in at least three enzymatically inactive forms: proPSA, benign PSA 
(bPSA), and intact PSA (iPSA), of which proPSA and benign PSA are the best 
characterized [24]. Whereas benign PSA is preferentially expressed in the transitional 
zone of the prostate and is associated with benign hyperplasia, the proPSAs are mainly 
expressed in the peripheral zone where malignant disease is most common [25,26]. 
ProPSA exists in at least three different molecular forms, where a pro-leading amino 
acid sequence can be truncated to different lengths, namely [-2]proPSA, [-4]proPSA, 
and [-7]proPSA [27]. Increasing interest has been paid to the different molecular forms 
of PSA as biomarkers. Total PSA and free PSA are discussed below, and the 
incorporation of molecular forms of free PSA and human kallikrein 2 (hK2) into 
predictive models are discussed in section 2.3.4 (Suggested biomarkers). 
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Figure 2: Outline of the molecular forms of PSA discussed. 
 
 
 
 
1.3.3.2 PSA as a biomarker for prostate cancer 
1.3.3.2.1 Total PSA 
The levels of PSA in men with no known prostate cancer increase with age [28]. This is 
illustrated by unpublished data from our group showing the median PSA level in 
346,221 men with no known prostate cancer or no previous prostate biopsy who came 
for their first PSA test in Stockholm County between 2003 and 2012 (STHLM0 data, 
see 5.1).  
 
Figure 3: Median PSA levels in 346,221 men in Stockholm County with no known prostate cancer and no 
prostate biopsy (unpublished data). 
 
 
Despite the association of PSA with age and benign prostatic conditions, PSA levels 
are firmly associated with both the risk of significant (high-grade, high-volume) 
prostate cancer and the long-term risk of prostate cancer-related metastasis and death. 
The implementation of PSA as biomarker has revolutionized prostate cancer 
diagnostics, with a subsequent increase in the incidence of prostate cancer, but the test 
has limited specificity due to a number of biological and analytical factors [20]. The 
total PSA level varies approximately 20% due to temporary biological variation, thus 
affecting the interpretation of a single result [29]. There is additional variation between 
different commercial PSA assays, and care must be taken in interpreting consecutive 
PSA measurements that have been made according to different calibration standards 
(e.g. traditional vs. WHO calibration). Furthermore, common 5-α-reductase inhibitor 
PSA
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medication against benign prostatic hyperplasia roughly halves PSA concentrations, 
mostly affecting the PSA produced by benign tissue, and PSA has been suggested to 
have better AUC for detecting prostate cancer in men on finasteride [30].   
 
No single tPSA cutoff differentiates men with significant cancer from those with 
insignificant cancer (i.e. low-grade, low-volume). Similar to the presence of prostate 
cancer, high-grade cancer can be found in men with low total PSA levels. While high 
PSA levels correlate with a high risk of prostate cancer, men with moderately increased 
PSA levels (4‒10 ng/ml) can show either malignant or benign findings. Sensitivity and 
specificity for PSA in finding prostate cancer have been estimated using 5578 men in 
the placebo-arm of the PCPT-trial (see Section 1.5.1; Age 55+; initial PSA ≤ 3ng/ml), 
which had a biopsy during the 7-year study. This study included invitation to end-of-
study biopsies for all participants. From Table 5 it can be seen that there is no PSA cut-
off with ideal properties, but rather a continuum of prostate cancer risk at all values of 
PSA[31]. PSA performance was slightly better in younger men (<70 years) compared 
to elder, possibly explained by the fact that PSA increases with age.  
 
Table 5: Sensitivity and specificity for prostate cancer by PSA-levels. From the PCPT trial [31] 
 Any prostate cancer Gleason grade ≥7 
PSA (ng/ml) Sensitivity Specificity Sensitivity Specificity 
1.1 83 39 93 37 
2.1 53 73 76 67 
3.1 32 87 58 82 
4.1 21 94 40 90 
6.1 5 99 13 98 
 
Even in men with PSA< 4 ng/ml, about 15% will have prostate cancer and 2% will 
have high-grade disease [32]. This is illustrated by unpublished data from the STHLM0 
cohort involving 32,348 men without prostate cancer coming for their first prostate 
biopsy (Figure 4). 
 
Figure 4: Cancer proportion findings in 32,348 men in Stockholm County without prostate cancer who 
came for their first prostate biopsy. The men were stratified by integer PSA value and the mean proportion 
of cancer was calculated (unpublished data). 
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In contrast to this, increasing interest have been paid to baseline, mid-life 
measurements of PSA where low PSA concentrations are associated with a very low 
risk of death from prostate cancer in the long term. Using blood samples collected in 
1981 from an unscreened population, Vickers and colleagues showed that a PSA level  
below median (1 ng/ml) by the age of 60 is associated with only a 0.5% risk of 
metastasis and a 0.2% risk of death from prostate cancer by the age of 85. This 
corresponded to 95% of deaths from prostate cancer being in men with baseline PSA 
above the population median at 60 years of age [33]. These results were corroborated 
by Ørsted and colleagues using samples collected in 1981‒1983 from 4,383 Danish 
men. The absolute 10-year risk of prostate mortality if men had a PSA level below 1 
ng/ml was < 1% in every age group, except men aged 60‒64, where it was 1.4%. The 
risk of any clinical prostate cancer generally followed this pattern, with a 10-year 
absolute risk of 0.5‒1.5% if PSA levels were < 1 ng/ml [34]. This has instigated 
suggestions that PSA tests should be recommended for men in their late 40s, while it 
could preclude a large number of men from further testing and the subsequent risk of 
over-diagnosis [35].  
 
1.3.3.2.2 f/t PSA 
PSA of men with malignant disease is less prone to proteolytic activity, and these men 
have a higher proportion of complexed PSA [36]. The ratio of uncomplexed (free) PSA 
to total PSA (f/t PSA) has been shown to increase test specificity. A prospective study 
of 773 men found that AUC increased from 0.53 using tPSA to 0.72 using f/t PSA in 
men with tPSA levels of 4‒10 ng/ml and benign DRE findings. In these men, cancer 
was found in 56% of those with f/t PSA < 0.10 but only in 8% of those with f/t PSA > 
0.25. A f/t PSA cutoff of 0.25 was therefore suggested for use in the PSA range 4‒10 
ng/ml where total PSA lacks adequate performance [37,38]. In 2005, a meta-analysis 
showed that 7‒34% of biopsies could be saved at the cost of missing 2‒20% of the 
cancers if f/t PSA cutoffs of 0.18‒0.26 were introduced when deciding on biopsy in 
men with PSA levels of 4‒10 ng/ml [39].  
 
1.3.3.2.3 PSA dynamics and PSA density 
The progress of prostate cancer is often reflected in PSA levels. Conceptually, 
progression of PSA can be defined in terms of PSA doubling time (PSAdt), reflecting 
an exponential increase in PSA, or PSA velocity (PSAv), reflecting an annual change in 
PSA. Historically, repeated studies have not shown any clear value of PSA velocity in 
the diagnosis of prostate cancer, possibly due to the biological variability of PSA, 
background noise (e.g. benign prostate hyperplasia), and variations in intervals between 
PSA measurements [40,41]. However, recent studies including a meta-analysis and a 
statistically advanced modeling of 219,388 men in the Kaiser Permanente health plan 
have shown that repeated measurements of PSA improve the detection of advanced 
prostate cancer as compared to a single measurement [42,43]. In summary, there is an 
ongoing debate on the value of PSA dynamics in aiding decisions about prostate biopsy 
[44,45]. 
 
PSA level depends on the size of the prostate gland, and PSA level divided by prostatic 
volume (PSA density, PSAD) has been associated with the risk of finding cancer [46]. 
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An early study on 565 men identified a cutoff for deciding on biopsy of PSAD = 0.15 
in men with moderately increased PSA (4‒10 ng/ml) to save performing half of the 
biopsies (77/142) at the cost of missing about every tenth cancer (2/23) [46]. PSAD has 
also been associated with stage and grade, and possibly gives prognostic information 
[47]. Additional studies have, however, been conflicting, and the additional value of 
both PSA dynamics and PSA density has been questioned by the authors of the PCPT 
study [48].   
 
 
1.3.4 Suggested biomarkers 
1.3.4.1 Kallikrein-related biomarkers 
Free PSA is composed of at least three different types of enzymatically inactive PSA: 
benign PSA (BPSA), intact PSA, and proPSA. ProPSAs are expressed in the peripheral 
zone and exist in several truncated forms. Through sequential steps, [-7]proPSA is 
truncated to PSA or [-2]proPSA. The latter has been suggested as a new prostate cancer 
biomarker [24,49]. Human kallikrein 2 (hK2) shows extensive amino acid sequence 
similarity with PSA and regulates proPSA activity.  It is present in plasma in much 
lower concentrations than PSA, and it has been repeatedly shown to improve 
discrimination between men with and men without prostate cancer [50].  
1.3.4.1.1 The four-kallikrein panel (4Kscore) 
With the development of analytical techniques, recent attempts to increase test 
performance have included the development of predictive models. The group of 
Vickers and Lilja has explored a statistical model based on measurements of total and 
free PSA, intact PSA, and hK2. Based on logistic regression with linear terms (PSA 
and free PSA) and non-linear terms (intact PSA, hK2), the prediction model has been 
shown to improve discrimination between men with and without prostate cancer. 
Several studies have addressed the situation of biopsy decision in men with elevated 
tPSA. Using 2,914 men from the Rotterdam arm of the European screening study 
ERSPC (see section 1.4.1) where 28% of initial biopsies detected cancer, AUC for 
prediction of cancer in biopsy increased from 0.64 using only information on PSA and 
age to 0.76 with addition of information on the four-kallikrein panel. Use of the model 
saved 49% of the men from undergoing prostate biopsy―at the cost of missing 14% of 
high-grade cancers [51]. These results have been shown to be relatively stable through 
replication using the French and Gothenburg arm of the ERSPC [52,53].  
 
Table 6: Overview of performance of the four-kallikrein panel aiding first biopsy decision in selected 
studies 
    AUC for all PCa 
Reference Year No. of 
participants 
PSA range 4K Base model 
Vickers et al. 2010 2,914 ≥ 3 0.76 0.64 
Vickers et al. 2008 740 ≥ 3 0.83 0.68 
Benchikh et al. 2010 262 ≥ 3 0.78 0.63 
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Using 1,501 men coming for their second or third round of screening with an elevated 
PSA, the model performed slightly less efficiently, potentially reducing the number of 
biopsies by 36% and missing 7% of high-grade cancers (4/61). The four-kallikrein 
panel has also been validated for the re-biopsy setting, where patients with high risk of 
prostate cancer have undergone a first biopsy with benign findings, and the decision 
must be based on repeated biopsies. In 925 men with PSA > 3 ng/ml and a previous 
biopsy with benign findings, the four-kallikrein panel had superior AUC both when 
predicting all and high-grade (Gleason score ≥ 7) prostate cancer as compared to using 
tPSA and DRE alone (AUC for PCa = 0.68 vs. 0.58 and AUC for high-grade PCa = 
0.87 vs. 0.76). In this cohort, with a proportion of cancer findings in the biopsies 
performed of 12%, the four-kallikrein panel potentially saved 54% of biopsies at a cost 
of missing 5% of high-grade cancers (1/19) and 34% of all cancers (37/119).  
 
The panel has also been evaluated in 392 men undergoing radical prostatectomy for 
prostate cancer, where it added prognostic value when predicting aggressive disease 
(defined by the surgery specimen; pT3-T4, extracapsular growth, Gleason component 
4‒5, high tumor volume). This indicates that a number of unnecessary surgeries for 
insignificant tumors could possibly be avoided by implementing the panel [54]. 
The four-kallikrein panel is under commercialization by OPKO Health Ltd., under the 
name 4Kscore, where the model has been calibrated to give the risk of finding a high-
grade cancer in a biopsy.    
 
1.3.4.1.2 Prostate Health Index 
Similarly, Beckman Coulter Inc. has commercialized the use of [-2]proPSA in the 
Prostate Health Index (PHI) algorithm, which uses the concentrations of [-2]proPSA 
together with tPSA and fPSA. PHI is calculated as [-2]proPSA/freePSA*√total PSA. 
PHI was developed with the aim of being a decision making tool in men with 
moderately elevated PSA with benign DRE findings [24].  
 
One of the first study of PHI performance used 2,034 men with PSA 2,5‒10 ng/ml and 
found an AUC of 0.77 when predicting all prostate cancer, which was superior to the 
use of both tPSA (AUC 0.50) and fPSA (AUC 0.68) [55]. Jansen and colleagues used 
756 samples from men with PSA 2‒10 ng/ml in two countries: the Rotterdam arm of 
ERSPC and the University of Innsbruck. They found that PHI increased AUC from 
0.68 to 0.76 in predicting all cancer when compared with a base model [56]. One 
European five-site prospective study on 646 men with PSA levels of 2‒10 ng/ml 
showed somewhat lower AUC (0.71 and 0.65, predicting all PCa and high-grade PCa, 
respectively), but still that 15% of biopsies could be avoided at the cost of missing 1% 
of high-grade cancers at the commonly suggested PHI cutoff of 27 [57]. Similarly, a 
European prospective study of 268 consecutive men with PSA 2‒10 ng/ml who were 
undergoing initial saturation biopsies (18‒24 needles) showed that PHI had superior 
AUC (0.76 and 0.72) compared to both tPSA and fPSA when predicting all PCa and 
high-grade PCa (Gleason score ≥ 7) [58]. Cutoff levels for PHI for initial biopsy 
decisions have been discussed by Catalona et al., using a multicenter approach with 892 
men. They found a somewhat lower AUC for all prostate cancer (0.70) and argued that 
an option for men with a PHI of < 25 was to be followed with subsequent blood tests 
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rather than undergo prostate biopsy (having 11% risk of finding prostate cancer on 
biopsy) [59]. 
 
Table 7: Overview of PHI performance for aiding first biopsy decision in selected studies 
    AUC for all PCa 
Reference Year No. of 
participants 
PSA range PHI Base model 
Le et al. 2010 2,034 2.5‒10 0.77 0.50 
Jansen et al 2010 756 2‒10 0.76 0.68 
Lazzeri et al. 2013 646 2‒10 0.71 0.65 
Catalona et al. 2011 892 2‒10 0.70 0.53 
Guazzoni et al. 2011 268 2‒10 0.83 0.72 
 
 
The performance of PHI in the initial and re-biopsy settings has been validated further 
in one European four-site prospective study involving 1,362 men with PSA levels of 
1.6‒8 ng/ml, showing similar results (AUC for all PCa = 0.74). For predicting outcome 
after radical prostatectomy (pT3 and/or Gleason score ≥ 7), PHI significantly enhanced 
AUC in a multivariate regression analysis, but only by 2%, and there was no evidence 
of clinical benefit in decision curve analysis [60]. 
   
In summary, both the four-kallikrein panel and PHI have been shown to increase test 
performance compared to the traditional variables tPSA, fPSA, and age when 
predicting prostate cancer in men coming for biopsy. All published studies are limited 
by the fact that men with low PSA levels are excluded from biopsy, even though we 
know that they can harbor significant cancer [32]. 
 
1.3.4.2 Single-nucleotide polymorphisms (SNP) 
From twin studies, it is estimated that heritable factors explain 42% of the risk of 
having prostate cancer [61]. Indeed, the relative risk of being diagnosed with prostate 
cancer is 2‒3 fold in brothers and sons of men with the disease, with increasing risk if 
the father is diagnosed at a young age [62,63]. However, more recent studies have 
indicated that increased diagnostic activity among the relatives of cancer patients 
contributes to this estimated increased risk, introducing detection bias in genetic and 
epidemiological studies of familial prostate cancer [64].  
 
Attempts to decipher the heritable component of prostate cancer based on candidate 
gene association studies and genome-wide linkage studies in multiple-case families 
have suggested numerous important genes and loci. However, the inability to replicate 
findings suggests that prostate cancer risk is genetically complex and affected by 
several low-penetrance genes [65].  
 
Single-nucleotide polymorphisms (SNPs) are single basepair-alterations that occur in 
the human genome when the single nucleotide (A, T, C, or G) varies at a specific 
location in the genome. SNPs are known to underlie differencies in how susceptible we 
are to diseases. They are easy to measure, and only need to be measured once, making 
them interesting in risk prediction models [66]. Chromosome 8q24 was the first region 
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to be identified in this context, and has the highest number of independent SNPs 
associated with prostate cancer. Since 2006, 25 prostate Genome-Wide Association 
Studies (GWAS) have been catalogued [67]. More than 55,000,000 SNPs have been 
described, and with the recent addition of 23 SNPs, 100 have been shown to be 
associated with the risk of prostate cancer. Known SNPs account for approximately 
33% of the familial risk of prostate cancer [68].  
 
Using data from men of different ethnicities collected in consorts, and using new 
whole-genome sequencing techniques, it is anticipated that future GWAS will identify 
even more genetic variants associated with disease. It has, however, been questioned 
whether these new SNPs will add value over the currently known ones[66,69]. So far, 
the risk-associated SNPs identified appear to be mainly associated with overall prostate 
cancer risk, and do not discriminate between aggressive and less aggressive disease. 
 
1.3.4.3 Single-nucleotide polymorphisms as biomarkers 
The development of robust and cheap genotyping devices has accelerated the interest in 
SNPs as blood-based biomarkers for cancer detection. Typically, harboring of one risk-
SNP is associated with a small increase in risk (OR = 0.74‒1.51), but in 2008 it was 
shown that a combination of five SNPs plus family history was associated with a 
significant cumulative effect on the risk of prostate cancer [70]. Subsequent studies 
have confirmed that about 10% of the male population can be identified by SNPs to 
have three times the median population risk of developing prostate cancer, and 1% of 
the population has been shown to have a 4.7-fold higher risk [68,71].  
 
A genetic risk score can be calculated by summing the number of risk alleles (0, 1, or 
2) at each of the SNPs measured, multipying it with the logarithm of that SNP’s odds 
ratio for prostate cancer, and divide by the total number of analyzed SNPs, as used in 
Paper II. With this approach, our research group studied 5,241 men undergoing prostate 
biopsy as part of clinical practice (STHLM1). A genetic score based on 35 SNPs was 
constructed and estimated to potentially save 23% of biopsies at the cost of missing 8% 
of aggressive cancers. There was a moderate increase in AUC from 0.64 to 0.67 when 
the genetic score was added to a model of PSA, f/tPSA, and age. The genetic score was 
associated with the risk of prostate cancer (OR = 1.52; 95% CI: 1.45–1.59) [72]. 
 
The genetic score has also been evaluated in a re-biopsy situation in 1,654 men from 
the control arm of the REDUCE trial [73]. In this study, increasing genetic score was 
associated with the risk of both all and high-grade prostate cancer on re-biopsy (OR = 
1.72 and 1.61, respectively). Also in this context, the increase in AUC when comparing 
a clinical model with and without the genetic score was modest (AUC = 0.62 vs. 0.66).  
1.3.4.4 Risk calculators 
Several additional statistical models incorporating biomarker levels have been 
suggested, while biomarkers reported individually do not perform well enough to 
replace PSA as the biomarker of choice in prostate cancer detection. The performance 
of two risk calculators in particular has been explored repeatedly. 
 
The American PCPT was a double-blind randomized trial designed to assess 
chemoprevention of prostate cancer with finasteride. It included men aged more than 
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54 years with a PSA level ≤ 3 ng/ml and a normal rectal examination (DRE). 
Participants underwent prostate biopsies if PSA exceeded 4 ng/ml, and the study also 
included invitation to end-of-study biopsies for all participants. A risk calculator for 
predicting high-grade cancer (Gleason	 ≥ 7; PCPTHG) was developed from 5,519 men 
in the control arm who all underwent six-core biopsies (4.7% of whom had high-grade 
disease). The calculator include the risk factors PSA, DRE, African origin, age, and 
history of a previous biopsy [41]. A major benefit of the model is that it only contains 
information that is easily obtainable during outpatient visits and is readily available 
through websites. It does not, however, include fPSA, f/tPSA, or prostate 
volume―possibly weakening the results. Recently, the PCPTHG was externally 
validated in 10 international cohorts (25,512 biopsies; European, US, and UK cohorts). 
In that study, the PCPTHG discriminated better than PSA in 8 of 10 cohorts but the 
overall AUC was only a few percentage points better when making predictions using 
the risk calculator (AUC = 74.6 vs. 71.5). PCPTHG gives prediction in terms of 
percentage risk of high-grade cancer, but the model overestimated the risk of high-
grade disease, especially in the first screening round in the Gothenburg and ERSPC 
trials. The calibration was better in re-screened men in the US and UK cohorts, and the 
model never performed worse than PSA [74].  
 
The ERSPC risk calculators (www.prostatecancer-riskcalculator.com) consist of 
several calculators incorporating age, urinary symptoms, and family history (Calculator 
1); PSA level (Calculator 2); and PSA in combination with DRE, prostate volume 
assessed by ultrasound (TRUS), and biopsy history (Calculators 3‒5). The ERSPC 
group have argued that risk calculators should include prostatic volume since PSA level 
is volume-dependent, and the ERSPC calculators have outperformed the PCPT 
calculators in European and Canadian populations, and have performed well in a Asian 
population [75-77]. 
 
These risk calculators are being developed continuously, and additional biomarkers will 
probably be added in time. For example, a second version of the PCPT risk calculator 
(PCPTv2) incorporating fPSA has proven to be promising [78]. Furthermore, the urine 
tests PCA3 and TMPRSS2-ERG (see below) have been shown to add predictive value 
to the ERSPC calculator [79].  
 
1.3.4.5 Other risk-assessment tools 
Searching PUBMED for (“prostate cancer” and biomarker) yielded 19,083 hits on 
November 15, 2014.  Despite these scientific efforts, only total and free PSA are of 
widespread use today―and the above-mentioned alternatives are the closest upcoming 
blood-based competition. However, tests based on urine have also been explored and 
are available in clinical practice, although to a limited extent. Furthermore, magnetic 
resonance imaging (MRI) has been increasingly explored for aiding biopsy decisions, 
targeting of lesions, and assessing patients after diagnosis of prostate cancer. To put 
them in context, these alternative risk-assessment tools are described briefly below. 
1.3.4.5.1 Urine biomarkers 
Prostate cancer gene 3 (PCA3) transcribes a prostate-specific mRNA that has shown 
promise as a diagnostic tool for prostate cancer. The PCA3 test (Progensa; Gen-Probe, 
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San Diego, CA) has been much studied and is in limited clinical use. It is of limited 
value for screening, while three strokes of prostatic massage during a DRE are needed 
for sufficient informative rate. When comparing ROC curves, virtually all studies have 
shown superiority of the PCA3 score to tPSA in predicting biopsy outcome [80,81]. 
However, a head-to-head comparison between tPSA and PCA3, trying to minimize 
attribution bias, indicated that PCA3 suffers from weaknesses similar to those with 
PSA, although to a lesser extent [82]. David Crawford and colleagues reported on 
1,962 prospectively recruited men with PSA levels > 2.5ng/ml. As when analyzing 
performance of PHI and the 4K panel, they found that a number of high-grade cancers 
would be missed if one applied a low (10) or a high (35) PCA3 cutoff for biopsy, but 
35% of biopsies could be avoided if one applied the low cutoff before deciding on 
biopsy [83]. The European Association of Urology states that the primary indication for 
PCA3 is to aid decision making on repeat biopsy following a benign first biopsy, but 
the cost-effectiveness remains to be seen [4]. The use of PCA3 is not supported by 
Swedish guidelines [2].  
 
In prostate cancer, the transmembrane protease serine 2 (TMPRSS2) gene can be fused 
to an oncogene (ERG) building the gene-fusion TMPRSS2-ERG. The resulting 
TMPRSS2-ERG protein is present in approximately half of all prostate cancer patients. 
In 2006, TMPRSS2-ERG was detected in urine and showing promising specificity for 
prostate cancer. Although studies have shown contradictory results, several have 
reported an association between presence of TMPRSS2-ERG and prostate cancer stage 
and prognosis [84]. Neither the use of PCA3 nor the use of TMPRSS2-ERG was 
recommended by the Swedish Board of Medical Evaluation (SBU) in 2011 [85]. 
 
Both PCA3 and TMPRSS2-ERG have shown independent values when added to the 
ERSPC risk calculator including tPSA, fPSA, age, previous biopsy history, and DRE 
[79].  
1.3.4.5.2 Magnetic Resonance Imaging (MRI) and MRI/UL-fusioned biopsies 
Future aids for decision in prostate cancer must efficiently minimize the number of 
diagnosed tumors that would not have affected the individual if untreated (i.e. minimize 
over-diagnosis). One strategy for achieving this is, instead of sampling the prostate 
gland systematically, to only direct biopsy needles to suspected lesions―possibly 
detected by MRI.  
 
Enhancement of MRI performance including functional techniques with spectroscopic 
imaging, dynamic contrast-infusion (DCE), and diffusion-weighted imaging (DWI) can 
be used. Spectroscopic imaging provides accurate metabolic information, but it is time 
consuming. DCE visualizes vascularity and neoangiogenesis, shows high sensitivity, 
but is limited by the lack of standardized protocols and analytical models. Of the 
functional MRI techniques, DWI is the most readily used, relying on the fact that the 
freedom of movement of water molecules (the diffusion coefficient) is restricted in 
cancer lesions due to reduced extracellular space [86]. 
 
MRI images can be used with biopsy needle placement when in the MRI tube (“in-
bore” biopsies) or by fusing the images to ultrasound (UL/MRI fusion), enabling 
tumor-guided biopsies using ultrasound in a regular outpatient setting. In-bore biopsies 
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are accurate, but they are time and cost consuming [87]. UL/MRI fusioned biopsies are 
intuitively attractive and have been explored prospectively by Pokorny and colleagues. 
These workers performed both fusioned biopsies against MRI-detected lesions and 
traditional systematic biopsies in 223 asymptomatic men. They found that 29% of 
cancers were not located in the peripheral zone, which is traditionally the only biopsied 
part of the prostate. Sensitivity and specificity of the fusion biopsies were superior to 
those of the systematic biopsies, and they concluded that compared to traditional 
biopsies fusion biopsies reduce the detection of low-risk cancers (n = 43 vs. 97), reduce 
the need for biopsy (n = 142 vs. 223), and improve the overall detection of 
intermediate/high-risk prostate cancer (n = 93 vs. 79) [88] (Table 8). 
 
Table 8: Histology of systematic biopsies and UL/MRI fusioned biopsies in 223 consecutive asymptomatic 
men. Combined histology was determined by the highest-risk tumor by either biopsy method. From 
Pokorny et al. [88] 
Histology result Systematic biopsies Fusion biopsies Combined findings 
Benign 97 43 81 
Low-grade cancer 47 6 34 
Intermediate/high-risk 
cancer 
79 93 108 
Total 223 142 223 
 
 
1.4 SCREENING FOR PROSTATE CANCER 
The underlying concept of screening is that early detection of risk factors or early 
disease is beneficial for clinical or public health outcome. As early as in 1968, Wilson 
and Jungner suggested a number of criteria to be met before introducing a screening 
program in a population [89]. Since then, criteria have been refined, but can still be 
summarized in the following four categories: (A) knowledge of the disease 
(importance for health, natural history, time from sub-clinical disease to overt disease, 
benefits of early detection); (B) the test (validity, reliability, cost); (C) the diagnosis 
and treatment (availability, cost-effectiveness, sustainability, harm/benefit balance); 
and (D) the screening program (who should be treated as a patient, health economy). 
 
Several studies have addressed the effects of PSA-based screening for prostate cancer, 
of which the randomized trials ERSPC and the PLCO have been the most prominent 
and have sparked a vivid scientific debate. ERSPC included 182,160 men aged 50‒74 
years from six European centers, randomly assigned to either a group that was offered 
PSA screening or a control group that did not receive any PSA screening. Men in the 
screening group underwent 2‒5 PSA screening rounds at 4-year intervals (10 rounds 
and 2-year intervals in the Swedish arm). A cutoff of 3 ng/ml was used as indication for 
biopsy. The ERSPC found a 21% lower relative risk of prostate cancer mortality after 
13 years in PSA-screened men (rate ratio = 0.79; 95% CI: 0.69‒0.91) [90]. This 
corresponds to 781 men having to be invited to screening and 27 men having to be 
diagnosed for each prostate cancer death avoided. The Gothenburg randomized trial 
was initiated in Sweden and involved 20,000 men randomized to biannual PSA 
screening or to a control group not invited for testing. Background PSA testing in 
Sweden was very low, and after 14 years of follow-up the cumulative prostate cancer 
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incidence was 12.7% in the screening group and 8.2% in the control group. The 
mortality from prostate cancer was almost halved (rate ratio = 0.56; 95% CI: 0.39‒
0.82) in screened men after 14 years. Overall, 293 men needed to be screened and 12 
needed to be diagnosed to prevent 1 prostate cancer death at 14 years. The Gothenburg 
trial reported most of its patients to the ERSPC [91].  
The American PLCO trial was instigated approximately simultaneously with ERSPC. It 
included 76,685 men aged 55‒74, and men in the screening arm underwent annual PSA 
testing and rectal palpation. American men used PSA testing earlier than European 
men, and at least 40% of men in the PLCO control arm had their PSA taken during the 
study. In addition, almost a third of the men in each arm had had a PSA test before the 
trial (pre-screening). From this, it might be expected that the power of the trial would 
be reduced. It has therefore been argued that the PLCO is underpowered and not a 
screening trial, but rather a comparison between different approaches to screening (i.e. 
opportunistic vs. systematic) [92,93]. The PLCO showed no mortality benefit with PSA 
screening after 13 years, finding no difference in disease-specific mortality rates 
between the groups (RR = 1.09; 95% CI: 0.87‒1.36). The incidence of prostate cancer 
was generally higher in the screening arm than in the control group (RR = 1.12; 95% 
CI: 1.07‒1.17) [94].  
Prostate cancer screening did not significantly decrease prostate cancer-specific 
mortality in a combined meta-analysis of five trials done by the Cochrane Library 
[95].  
A major drawback of PSA screening is the increased prostate cancer detection in men 
with disease that would not have affected their lives if not diagnosed, resulting in high 
risk of over-treatment. Using microsimulation models, it has been demonstrated that the 
benefit of PSA screening in ERSPC was diminished by loss of quality-adjusted life-
years (QALY), owing to long-term effects caused by side effects of diagnosis and 
treatment [96].   
 
In order to concentrate screening on those who benefit, Carlsson and colleagues 
recently studied stratified screening. They compared risks of prostate cancer metastasis 
and death in two PSA-stratified cohorts of men aged approximately 60 years, the first 
from the screened arm in the Gothenburg screening trial (screening) and the second 
from the historical Malmö Intervention trial (control). They reported that for men aged 
60 years with an initial PSA level of ≥ 2 ng/ml, only 23 needed to be screened and six 
needed to be diagnosed to prevent one death after 15 years. In contrast, men with PSA 
levels < 1 ng/ml had a very low risk of metastasis and death [97]. 
 
In summary, many authors have argued that the time for population-based screening 
using PSA levels has not arrived [90]. Instead, following five golden rules for 
transforming PSA screening in order to minimize over-treatment has recently been 
suggested: (1) Obtain consent from the participants; (2) Do not screen men who 
will not benefit; (3) Do not perform biopsy without a compelling reason; (4) Do not 
treat low-risk disease; and (5) If treating, do so at high-volume centers [98].  
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In line with this, today most organizations addressing this issue do not recommend 
screening with PSA, but rather offering early diagnostics and treatment to well-
informed men. The American Urological Association recommends shared decision 
making and― if agreed―PSA testing at intervals of two or more years in men aged 
55‒69 years, possibly also in younger men with high risk due to heredity or ethnicity. A 
recent Best Practice Statement update suggested that the age for obtaining a baseline 
PSA be lowered to 40 years and the single PSA threshold for biopsy should be replaced 
by a decision based on tPSA, DRE, f/tPSA, age, family history, previous biopsy 
history, and comorbidities [99]. 
 
The National Comprehensive Cancer Network (NNCN) recently uniformly 
recommended that baseline PSA testing should be recommended for healthy, well-
informed men aged 50‒70 years, with a lower grade recommendation also for men 
aged 45‒49 years. Testing in men > 70 years should be performed with caution, and 
only in very healthy men with little comorbidity―since these men often harbor prostate 
cancer of insignificant importance. PSA testing should be repeated at 1- or 2-year 
intervals, except for men aged 45‒49 with PSA < 1 ng/ml where further testing can be 
deferred until the age of 50 [93].  
 
These recommendations followed on from the much discussed recommendation of the 
United States Preventive Services Task Force (USPSTF) in 2012 against PSA 
screening. They argued that there is convincing evidence that PSA-based screening 
programs result in the detection of many cases of asymptomatic prostate cancer, and 
that many men who have asymptomatic cancer detected by PSA screening have a 
tumor that either will not progress or will progress so slowly that it would have 
remained asymptomatic in the man’s lifetime (i.e. over-diagnosis). Because of the 
inability to identify tumors that will remain indolent from those destined to be lethal, 
many men are being subjected to the harms of treatment for prostate cancer that will 
never become symptomatic (i.e. over-treatment). Together with the Canadian Task 
Force on Preventive Health Care (CTFPHC), they argued that the benefit of a small 
decrease in prostate cancer mortality seen in the ERSPC trial does not compensate for 
the substantial risks of diagnosis-related psychological harm, biopsy complications, 
post-treatment side effects[100,101]. 
  
In 2013, the European Association of Urology published four statements, including that 
PSA screening reduces PCa-related mortality, that baseline serum prostate-specific 
antigen level should be obtained at 40–45 years of age, and that intervals for PSA 
testing should be 2‒8 years depending on the results of previous PSA testing [102]. In 
the most recent EAU guidelines on prostate cancer screening and early diagnosis, men 
are recommended to undergo biopsy after shared decision making, and using a 
threshold PSA for biopsy of 2‒3 ng/ml [4]. The Swedish guidelines from 2013 
recommend against PSA screening, but promote organized PSA testing in men aged 
50‒70 years after informed decision making [2]. 
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1.5 CHEMOPREVENTION 
Being a common disease causing a relatively high number of deaths, it is relevant to 
study possible chemoprevention in prostate cancer. To date, no pharmaceutical drug 
has been evaluated with sufficient results to be recommended for patients. However, a 
few medications have been suggested and have shown different levels of promise. Alfa-
reductase inhibitors have been studied in trials, but there have only been observational 
studies on aspirin, statins, and metformin.  
 
 
1.5.1 Alfa-reductase inhibitors 
5-alfa-reductase (5-AR) converts testosterone to di-hydrotestosterone, and can be 
inhibited by 5-alfa-reductase inhibitors (5-ARI; e.g. dutasteride and finasteride). Long-
term observations of individuals with inherited 5-AR defiency have shown a reduced 
growth of the prostate and diminished risk of prostate cancer, inspiring studies on 
prevention of prostate cancer with 5-ARIs [103]. Two large randomized trials have 
been performed addressing the use of alfa-reductase inhibitors in preventing prostate 
cancer. The PCPT trial was designed to assess the ability of finasteride to reduce 
detection of prostate cancer in men at low risk of the disease. Finasteride reduced the 
risk of prostate cancer by 25%, but men in the treatment arm showed a slightly higher 
risk of high-grade cancer (6.4% vs. 5.1%). Sexual side effects were more common and 
urinary symptoms were less common in the treatment group than in the placebo group 
[104]. 
 
The REDUCE trial included men with PSA levels of 2.5‒10 ng/ml. The trial showed 
that dutasteride reduced the risk of prostate cancer by 23%, corresponding to an 
absolute risk reduction of 5%. However, there was no risk reduction for Gleason 7+  
tumors. In addition, there were significantly more cardiac events in the dutasteride 
group (0.7% vs. 0.4%) [105]. 
 
 
Table 9: Overview of the PCPT and REDUCE trials     
 PCPT (finasteride) [104] REDUCE (dutasteride) [105] 
n 18,882 8,231 
Age; PSA ≥ 55 years; ≤ 3 ng/ml 50‒75 years; 2.5‒10 ng/ml 
Follow-up 7 years 4 years 
All PCa 18.4% vs. 24.4%; p < 0.001 19.9% vs. 25.1%; p < 0.001 
High-grade PCa (Gleason 7+) 6.4% vs. 5.1%; p = 0.005 6.7% vs. 6.8% 
NNT to prevent one cancer 17 20 
PCa , prostate cancer; NNT, number needed to treat. 
 
 
A lively debate followed from the results of PCPT and REDUCE, especially about the 
risk of high-grade tumors in men treated with 5-ARI. Neither finasteride nor dutasteride 
has been approved by the FDA for prevention of prostate cancer. However, 18-year 
follow-up of the PCPT study showed no difference in overall survival or prostate 
cancer-specific survival between men treated with placebo or finasteride [106]. This 
  28 
suggests that 5-ARI reduces the risk of low-grade prostate cancer without affecting the 
long-term risk of death from prostate cancer. 
 
 
1.5.2 Aspirin 
There is laboratory evidence to suggest that chronic inflammation plays an important 
role in the etiology of cancer. Several studies have suggested a protective effect from 
anti-inflammatory drugs such as aspirin on the risk of developing various forms of 
cancer, including prostate cancer [107]. One meta-analysis by Bosetti and colleagues 
found a 10% reduced risk of prostate cancer in regular aspirin users, based on data from 
nine case-control and 15 cohort studies, although there was significant heterogeneity in 
the risk estimates and no relationship between risk reduction and frequency, dose, or 
duration of use [108]. Another, more recent, meta-analysis showed similar results with 
a significant inverse association between aspirin and the risk of both overall and high-
risk prostate cancer (OR = 0.92 and 0.81). In this analysis, there was also a significant 
association with prostate cancer mortality (OR = 0.86) [109]. At the same time, Shebl 
and colleagues used data from 29,450 men in the PLCO trial and showed a protective 
effect of daily aspirin on prostate cancer risk (HR = 0.92; 95% CI: 0.85‒0.99) [110]. 
However, in 2014 Veitonmäki used 78,615 men in the Finnish screening trial and 
reported an increased risk of prostate cancer in NSAID users (HR = 1.45; 95% CI: 
1.33‒1.59), but no significant association between prostate cancer and use of aspirin 
[111]. Murad et al. investigated associations between NSAID and aspirin use and 
prostate cancer risk in the ProtecT trial and found no protective effect, but they also 
reported an association between aspirin used and reduced serum PSA in controls [112].   
 
Algotar investigated 140 men with prostate cancer, showing lower baseline PSA in 
non-users of aspirin (PSA 5.2 ng/ml vs. 7.6 ng/ml) [113]. Fowke and colleagues 
investigated 1,277 men scheduled for prostate biopsy and found lower PSA levels in 
aspirin users (7.3 ng/ml vs. 12.7 ng/ml) [114] . While biopsy decisions are based on 
PSA levels, anything that lowers PSA levels might reduce the incidence of prostate 
cancer while some men are withdrawn from biopsy. Addressing this potential detection 
bias in observational studies is important. 
 
 
1.5.3 Statins 
Also being a very commonly prescribed medication, statins have been proposed as 
possible chemopreventive agents. In a matched case-control study using data on 387 
men who died from prostate cancer, Marcella and colleagues found a substantial degree 
of protection against prostate cancer death in statin users (OR = 0.49; 0.34‒0.70) [115]. 
Tan et al. used a retrospective cohort design on 4,204 men undergoing prostate biopsy. 
They found a reduced risk of prostate cancer (RR = 0.86; 95% CI: 0.75‒0.97) and also 
less frequent high-grade prostate cancer [116]. Using the Veterans Affairs Health Care 
System, Farwell identified 55,875 American men on statin or hypertensive medication. 
Compared to men on antihypertensive medication, statin users were 31% less likely to 
be diagnosed with prostate cancers (HR = 0.69; 95% CI: 0.52‒0.90) [117]. A Finnish 
cohort study of 23,320 men participating in a screening trial demonstrated a dose-
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dependent reduced prostate cancer incidence among statin users as compared to non-
users (HR = 0.75; 95% CI: 0.63‒0.89). The inverse association was strongest for low-
grade and early-stage tumors [118]. It is especially interesting that this study―while 
using data from the Finnish PSA-screening study―described this effect and at the same 
time corrected for age-adjusted PSA levels. 
 
The effect on PSA from statin use is quite well established. A biological causality has 
been proposed, and cohort studies have shown lower PSA levels in statin users―as 
shown in a review by Mener [119]. He demonstrated this in a cohort of 962 patients, 
with 8% lower PSA levels among users [120], which is congruent with the findings of 
Murtola’s Finnish group [118]. 
 
 
1.5.4 Metformin 
Metformin is a biguanide with antihyperglycemic effects. It acts through reduction of 
liver production of glucose and by increasing the peripheral sensitivity to insulin. 
Common side effects include changes in taste and a diversity of gastrointestinal 
symptoms that most often diminish gradually.  
  
An increasing number of studies are investigating a possible association between 
metformin and the risk of cancer, although the results are contradictory. In 2012, a 
meta-analysis covering 37 studies (7 on prostate cancer) showed risk reduction for liver 
(78%), pancreatic (46%), colorectal (23%), and breast cancer (6%). However, no 
significant association between metformin and risk of prostate cancer was seen [121]. 
A later meta-analysis on mortality risk after cancer diagnosis in men with or without 
metformin has come to similar conclusions [122].  
 
In 2013, David Margel and colleagues published two articles on the association 
between metformin treatment and the risk of prostate cancer, its grade, and disease-
specific mortality [123,124]. The first was a registry-based retrospective nested case-
control study involving 5,306 diabetics on metformin and 26,530 diabetic controls. 
They found no significant association between metformin and any prostate cancer (OR 
= 1.03; 95% CI: 0.96‒1.1) or high-grade prostate cancer (OR = 1.13; 95% CI: 0.96‒
1.32) [124]. Using the same registry-based retrospective cohort, they published 
mortality data a few months later using a cohort study design with 3,837 diabetic men 
who developed prostate cancer. The cumulative duration of metformin medication was 
associated with a reduced risk of prostate cancer-specific death in a dose-dependent 
fashion (HR = 0.76; 95% CI: 0.64‒0.89) for every six months of additional metformin 
use, and the study sparked interest in a future randomized trial [123]. This finding was, 
however, questioned by Marjoleen Zanders in an article suggesting that confounding by 
indication might explain the 24% reduction in mortality per six months of metformin 
used―per se not entirely biologically plausible [125]. The term “confounding by 
indication” is usually used to denote a particular form of confounding in studies of 
medications where the apparent effect of a medication is actually a result of the 
condition for which it is prescribed. 
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2 AIMS 
2.1 OVERALL AIMS 
 
The overall aims of this thesis were to  
 
 
1. explore the current practice in prostate cancer testing  
2. evaluate proposed biomarkers for early detection of prostate cancer 
3. investigate chemoprevention of prostate cancer. 
 
 
 
2.2 SPECIFIC RESEARCH QUESTIONS 
During the project, several specific scientific questions were raised. Among these, this 
thesis was based on the following questions. 
 
2.2.1 Paper I 
How prevalent is testing and retesting of PSA? 
 
2.2.2 Paper II 
Is a genetic score based on single-nucleotide polymorphisms informative regarding the 
risk of prostate cancer in men with low PSA? 
 
2.2.3 Paper III 
Are the commercially available models PHI and the four-kallikrein panel comparable in 
aiding biopsy decisions? 
 
2.2.4 Paper IV 
Do commonly used medications affect PSA and the risk of prostate cancer on biopsy? 
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3 MATERIALS 
This thesis work was performed using data from two main sources that were organized 
during the project period. Paper I and Paper IV used data from the STHLM0 cohort and 
Paper III used data from the STHLM2 cohort. Paper II was a clinical study with 
subjects invited from STHLM2. 
 
3.1 STHLM0 
3.1.1 Base cohort 
The STHLM0 cohort covers all men in Stockholm County who have had a PSA test 
since 2003. It is continuously updated with data from all known laboratories in the area 
that perform PSA or biopsy analyses (Karolinska University Laboratories, Aleris, and 
Unilabs), involving up to 422,000 participants up to September 2014. Data on all 
analyzed PSA samples are continuously acquired together with SNOMED-coded 
biopsy results on each individual prostate biopsy session involving the cohort 
participants. The place of residence is determined through linkage with Statistics 
Sweden. The base cohort is then intermittently updated against the registers listed 
below, which are held by regional cancer centers, the Swedish National Board of 
Health and Welfare, and Statistics Sweden. 
 
STHLM0 is kept at the Department of Medical Epidemiology and Biostatistics, 
Karolinska Institutet, as an Oracle-based database, where researchers (after agreement) 
can access anonymized data for analysis.   
 
3.1.2 Registries held at the Swedish Board of Health and Welfare 
3.1.2.1 The Swedish Cancer Register 
The Cancer Register was started in 1958 and is the oldest health register in Sweden. It 
is held by the Swedish Board of Health and Welfare and reporting is mandatory by law. 
All physicians must report all new cases of cancer, and separate registrations are done 
by pathologists and cytologists with additional data. Thus, two separate departments 
identify most cancer cases. The register covers more than 96% of the approximately 
60,000 malignant tumors diagnosed annually in Sweden. It includes information on 
personal identity, sex, place of residence, diagnostic unit, ICD-coded tumor 
localization, date of diagnosis, and tumor stage at diagnosis as described by TNM 
status. Data are collected by the six regional cancer centers and quality assessment of 
the data is performed both by the cancer centers and the Board of Health and Welfare 
[127]  
 
3.1.2.2 The Swedish Cause of Death Register 
Since 1960, the causes of death of all Swedish citizens have been registered in the 
Swedish Cause of Death Register, which is updated on an annual basis. Since 1997, it 
has also included persons for whom the death certificate, but not the cause-of-death 
form, has been registered. The register includes variables on age at death, date of death, 
place of death, sex, and the immediate and contributory causes of death coded 
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according to the ICD (International Classification of Diseases). The register includes 
data on the cause of death in 98% of all deaths, and agreement between the registry and 
peer-reviewed journals has been reported to be 86% in prostate cancer patients, 
indicating a fairly high degree of validity [128]. 
 
3.1.2.3 The Swedish Prescription Register 
All prescription medications that are dispensed in Sweden are reported to the National 
Prescription Register, corresponding to 100 million prescriptions annually. The register 
is updated monthly and includes variables on patient ID, prescriber, place of 
prescription and expedition, the expedited medication code according to the ATC 
(Anatomical Therapeutic Chemical Classification System), and cost. It is increasingly 
used for scientific purposes, since the personal identification number of the patient has 
been included in the register from 2005. Data are collected by a collaboration service 
run by the pharmacies (Apotekens Service) and reported to the registry, which is held 
by the National Board of Health and Welfare. The coverage exceeds 99% of all 
prescriptions dispensed, indicating high validity. Despite this, the register must be used 
with caution for certain medicines, and medications bought over the counter are not 
registered. 
 
3.1.3 Registries held at Statistics Sweden (Statistiska Centralbyrån) 
3.1.3.1 Population and socioeconomic data 
Statistics Sweden (Statistiska Centralbyrån; SCB) holds a wide variety of data on 
Swedish citizens in the population registers (Registret över totalbefolkningen, 
Registret över inkomster och taxeringar (income register), Förmögenhetsregistret, 
Registret över Kapitalvinster och -förluster, Folk- och Bostadsräkningen) and activity 
registers (Befolkningens utbildning, Elevregistret, Komvuxregistret, Universitetens 
register, Lönesummestatistiken, Yrkesregistret). Furthermore, data are collected in 
surveys on household economy, salary structures, etc.   
 
Data on birth, death, and migration are kept on each Swedish citizen and are reported 
by the Tax Agency (Skatteverket) to the Total Population Register (Registret över 
totalbefolkningen).  
 
The population censuses (Folk- och Bostadsräkningen) have been performed several 
times, but most recently in 1990, which is why such data are becoming increasingly 
outdated. Instead, the register on education of the population (Befolkningens 
utbildning) and the economic registers provide important socioeconomic information. 
There is also important information in the Employment Register (Yrkesregistret), but 
this is more difficult to use while different professions are coded with low quality.  
 
The register on the population’s education is updated annually, and data on education 
accomplished is reported to the registry from all Swedish schools. Highest education 
achieved is coded according to SUN-2000 (Svensk UtbildningsNomenklatur) and 
entered together with personal identification number, place of education, and year of 
education. The SUN coding is stratified in seven levels, which are readily and often 
transcribed to three education strata representing 0‒9, 10‒12, and > 12 years of 
education (school, high-school, and further or higher education). 
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3.1.4 The National Prostate Cancer Register (NPCR) 
In the 1990s, all six Swedish regions established regional prostate cancer registries. In 
1998, the NPCR was created from these and is now held by a collaboration between the 
Regional Cancer Centers in Sweden. It includes diagnostic unit, date of diagnosis, and 
tumor stage according to the TNM classification system. It also includes extensive 
clinical information on Gleason grade, PSA level at diagnosis, and primary treatment 
within six months of diagnosis. Reporting is coordinated with reporting to the Swedish 
Cancer Register, and involves three different forms: one diagnostic form, one form on 
primary treatment, and a separate form on radiotherapy. Reporting is internet-based and 
voluntary. Of 103,047 men registered in the Swedish Cancer Register between 1998 
and 2009, 100,849 were registered in the NPCR, illustrating the very high capture rate 
[129,130].  
 
 
3.2 STHLM2 
3.2.1 Description 
Our research group collected the STHLM 2 cohort 
between November 2010 and September 2012. At 60 test 
laboratories in Stockholm County, all men coming for 
PSA testing were invited to give four extra tubes of blood, 
to give a urine sample, to have their blood pressure 
measured, and then to answer a questionnaire―building a 
population-based cohort. Altogether, 24,642 men were 
included during the 22-month study period. For the base 
cohort, no age restriction was used and participants could 
enter the cohort repeatedly if they came for repeat PSA testing. Historical PSA test 
data, biopsy records, clinical records, socioeconomic data, and prescription data were 
retrieved from the STHLM0 database.  
 
3.2.2 Collection and biobanking  
Apart from the blood drawn for standard PSA analysis, the study used separate study 
laboratory referrals for blood collection. Whole blood for plasma and DNA was 
collected in ethylenediaminetetraacetic acid (EDTA) tubes without gel. The tubes were 
transported to KI Biobank within 24 hours. Centrifugation and aliquoting of plasma 
(225 µl) was performed in an automated system and the samples were stored at −80oC. 
DNA was extracted using magnetic bead separation. Participants entered questionnaire 
data through a website or using mailed paper forms if preferred.  
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4 METHODS 
4.1 PAPER I 
For Paper I, the study population was defined as all males living in Stockholm County 
on May 28, 2012 (n = 1,034,129), as verified using data from the population register. 
Data on PSA tests, prostate biopsies, and cancer diagnoses in these men were retrieved 
from the STHLM0 cohort described above. Aggregated data on the study population 
were retrieved from Statistics Sweden. Historical population estimates were calculated 
for single years by multiplying the 2011 population by the probability of not 
immigrating to Stockholm in the intervening years. The calculation of historical 
population sizes enabled the calculation of test prevalence throughout the study period 
(2003‒2011). In papers I‒IV, STATA versions11‒13 (StataCorp LP, College Station, 
TX, USA) were used for the main parts of the statistical analysis. 
 
4.1.1 Prevalence calculations 
Duration-specific test prevalence was calculated as the number of men having a PSA 
test in Stockholm preceding a point in time divided by the population at that point in 
time. Prevalence was stratified in 10-year age groups excluding men outside the age 
range 40‒89 years. 
 
4.1.2 Survival analysis 
Pattern of PSA retesting was illustrated using survival analysis. Cumulative incidence 
of a second PSA test was calculated using time since the first test as underlying 
timescale. End of follow-up in the survival analysis was date of retesting, date of 
prostate cancer diagnosis, or December 31, 2011, whichever came first. We excluded 
men less than 40 or more than 89 years of age together with men who had previously 
undergone prostate biopsy and men with prostate cancer.  
 
4.2 PAPER II 
The study population of Paper II was men in STHLM2, aged 50‒69 years, coming for 
PSA testing without previous prostate biopsy or prostate cancer and with a PSA level 
of 1‒3 ng/ml. We identified 2,696 men from the STHLM2 cohort from whom we could 
make a stratified random selection based on a genetic score. 
 
Men were stratified and invited according to risk deciles, with the lowest risk decile 
corresponding to low risk, the highest decile corresponding to high risk, and the 
remaining deciles defining the intermediate risk group. The clinicians involved in the 
study were blinded regarding risk score, until data analysis. 
 
Considering that prostate biopsy can have medical side effects, we restricted the study 
size to meet the requirements stipulated by power calculations, and we over-sampled 
participants from the highest and lowest risk groups. Altogether, 860 men were invited 
by letter and 172 of them underwent prostate biopsy and complete data analysis (n = 
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50; n = 79; and n = 43 from the first, second to ninth, and tenth risk deciles, 
respectively); 668 men did not answer the invitation.  
 
4.2.1 Calculation of genetic risk score 
Blood plasma from the entire study cohort (n = 2,696) was genotyped for 50 single-
nucleotide polymorphisms (SNPs) identified as being associated with prostate cancer 
risk. Genotyping was performed using matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry based on allele-specific primer extension with iPLEX 
chemistry (SEQUENOM 96 Inc., San Diego, CA, USA). 
 
For each man, we created a genetic score by summing the number of risk alleles (0, 1, 
or 2) at each SNP and multiplying by the logarithm of that SNP’s reported odds ratio, 
then dividing by that man’s total number of called SNPs. Men were then assigned a risk 
decile according to genetic score rank. 
 
4.2.2 Sampling, biopsy procedure, and specimen evaluation 
In total, 192 biopsy occasions were arranged for invitees to book through an internet-
based booking system or by telephone. Biopsies were performed by myself or Dr. 
Markus Aly between May and December, 2012, following clinical guidelines. Between 
10 and 12 ultrasound-guided biopsies were taken from the peripheral zone. 
 
Each specimen was fixed separately, paraffin-embedded, and cut at 4 µm. Professor 
Lars Egevad, who was blinded regarding the PSA level and risk score of the 
participant, reviewed biopsies. 
 
4.2.3 Logistic regression analysis 
Associations between prostate cancer on biopsy and evaluated risk factors were 
explored in univariate and multivariate logistic regression analyses, using STATA 
software. The multivariable model included genetic risk score, total PSA, PSA ratio, 
age, prostate volume, digital rectal examination (DRE) findings, and family history. 
 
4.2.4 Net reclassification improvement (NRI) analysis 
Two multivariate logistic regression models including and excluding the genetic score 
were compared using net reclassification improvement (NRI). The NRI considers a 
situation where a given event is predicted by two models, in this case one model using 
tradition variables (total PSA, PSA ratio, family history, prostate volume, DRE) and 
one model using these variables plus the genetic score. 
 
The predicted probabilities of changing classification (cancer/no cancer) when 
changing between the models are calculated and NRI is then calculated as:  
 𝑁𝑅𝐼 = 𝑃 𝑢𝑝 𝑐𝑎𝑛𝑐𝑒𝑟 − 𝑃 𝑑𝑜𝑤𝑛 𝑐𝑎𝑛𝑐𝑒𝑟 − [𝑃 𝑢𝑝 𝑛𝑜𝑐𝑎𝑛𝑐𝑒𝑟 − 𝑃 𝑑𝑜𝑤𝑛 𝑛𝑜𝑐𝑎𝑛𝑐𝑒𝑟 ] 
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Where up/down is upward/downward classification (from no cancer to cancer and vice 
versa) using the new model and cancer/nocancer is the true value the model tries to 
predict. Followingly a suggested model should have a positive NRI to be of clinical 
value and the NRI ranges from −2 to 2 [131]. 
 
4.3 PAPER III 
Paper III compared the performance of three models (base model, PHI, 4K) predicting 
all and high-grade prostate cancer. It was a prospectively collected, observational study 
including men with PSA test taken before a prostate biopsy resulting in cancer 
diagnosis (cases) or benign findings (controls). We selected all new prostate cancer 
cases in the STHLM2 cohort and all men having a biopsy with benign findings after 
inclusion in STHLM2. For the main analysis, we only included previously unbiopsied 
men with PSA levels of 3‒15 ng/ml, while men with PSA < 3 ng/ml do not routinely 
come for biopsy and men with PSA > 15 ng/ml would often be biopsied regardless of 
the result of a new biomarker test. Clinical data were drawn from the STHLM0 
database. 
 
Biopsies were performed by clinicians in Stockholm according to clinical practice, 
including information on PSA levels, DRE findings, prostate volume, and family 
history. 
 
Plasma aliquots from the STHLM2 cohort were sent for analysis to the laboratories 
listed below: 
 
Biomarker Laboratory Analysis equipment 
Total PSA, free PSA  Karolinska Universitetslaboratoriet  Roche Modular E170 
[−2]proPSA Karolinska Universitetslaboratoriet UniCel Dxl 800 (Beckman 
Coulter) 
hK2, intact PSA Wallenberg research laboratory, 
Skåne University Hospital 
Research Assay[132] 
 
4.3.1 Evaluated biomarker models 
A base model with age and total PSA was modeled using logistic regression. The PHI 
score was calculated as [−2]proPSA/freePSA*√total PSA [24]. The four-kallikrein 
model was calculated by Andrew Vickers using a previously described method 
incorporating restricted cubic splines [133]. These models were then used to predict the 
risk of finding prostate cancer, providing entirely external validation. 
 
4.3.2 Receiver-operating characteristics (ROC) 
Discrimination was assessed using receiver-operating characteristic (ROC) curves and 
summarized using the area under the ROC curve (AUC). Briefly, the ROC curve 
illustrates the performance of a model with a binary endpoint (e.g. cancer/no cancer) 
over a set of threshold values (e.g. different levels of a biomarker). It is created by 
plotting the sensitivity (the probability of a positive test given that the patient is ill) 
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against the specificity (the probability of a negative test given that the patient is well) of 
the biomarker at various thresholds. 
 
4.3.3 Decision curve analysis 
Decision curve analysis was introduced by Vickers and Elkin in 2006 as a tool to 
evaluate whether new models improve clinical management of patients [134]. Briefly, 
decision curve analysis graphically illustrates the net benefit obtained from using the 
predictive models in a patient. This is done by assuming that there is a threshold 
probability of having prostate cancer at which a patient decides to undergo biopsy and 
assuming this is informative of how the patient weighs the relative harms of a false-
positive or false-negative prediction. This relationship is used to derive the net benefit 
of the model across different threshold probabilities. Plotting of net benefit against 
the threshold probabilities gives the “decision curve”. 
 
4.3.4  Calculation of the percentage of biopsies avoided 
Prostate biopsies cause harm in terms of physical pain, mental distress, risk of 
diagnosing cancer that would otherwise not have affected the person’s life (over-
diagnosis), and increasing infectious complications with antibiotic-resistant bacteria. 
Thus, it is essential that biomarker models that are introduced should increase test 
specificity, with maintained sensitivity for aggressive tumors. In short, it is of utmost 
importance to avoid unnecessary biopsies. 
 
The percentage of potentially avoided biopsies using a prediction model can be 
calculated as the number of avoided biopsies by different threshold levels of the 
biomarker. The calculation can be written (TP1 + FP1 − TP2 − FP2) / (TP1 + FP1), where 
TP and FP denote counts of true and false positives in the two models being compared. 
 
The number of missed cancers is equally important, and can be calculated as the false 
negatives. 
 
4.4  PAPER IV 
Paper IV was a retrospective registry-based cohort study addressing the association 
between aspirin, statin, and anti-diabetic medication on the one hand and PSA levels 
and the risk of finding prostate cancer in a biopsy specimen on the other. The 
underlying study population was drawn from the STHLM0 cohort, representing 
virtually all PSA-tested men in Stockholm. Since prescription data were available from 
2005, we included men undergoing a PSA test between 2007 and 2012, allowing a run-
in period and at least 12 months for verification of diagnosis.  
 
Exposure to medication was assessed through the prescription register, and drug use 
was defined as any prescription dispensed within two years before biopsy. Cumulative 
dose was calculated as quartiles of total dose in the two years preceding biopsy. 
The endpoints were (i) level of first PSA in men without prior prostate biopsy or 
prostate cancer and (ii) the risk of prostate cancer and high-grade prostate cancer in a 
man’s first prostate biopsy. Regression analysis was adjusted for education level 
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(achieved from Statistics Sweden), PSA levels, and Charlson Index (calculated from 
the National Patient Register). 
 
4.4.1 Calculation of differences in PSA level 
The distribution of tPSA in a population is left skewed due to the fact that men with 
advanced prostate cancer often show with very high PSA levels (thousands). Geometric 
means are a way of dealing with this, and can be calculated as 𝑔 = 𝑥!𝑥!… 𝑥!! , where 
x denotes the individual PSA measurements. To illustrate differences in PSA levels, we 
fitted a linear regression on natural log-transformed PSA levels with adjustment for 
age, comorbidity, and medications. We then calculated the anti-logs, giving the 
difference in PSA levels between groups in percentage points. 
 
4.4.2 Association between medication and biopsy result 
The association between a medication and the risk of finding prostate cancer in a man’s 
first biopsy was addressed using first univariate and then multivariate logistic 
regression adjusted for age, log-transformed tPSA, f/tPSA, comorbidity, educational 
level, and medication use. Outcomes (dependent variables) were both prostate cancer in 
general and high-grade prostate cancer defined as a Gleason score of ≥ 7. When 
analyzing high-grade prostate cancer, low-grade cancers were classified as controls 
together with benign findings. When analyzing subgroups of medications, other 
subgroups were excluded; for example, when analyzing the effect of hydrophilic 
statins, men using other statins were excluded from the analysis.  
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5 RESULTS 
5.1 PAPER I 
In the male population of 1,034,129 men in Stockholm 2011, we identified 229,872 
who had had a PSA test between 2003 and 2011. Median age for men having a PSA 
test was 64 years. We restricted the analysis to men aged 40‒89 years and the 
prevalence of having a PSA test is illustrated in table 10. 
 
Table 10: Population of Stockholm County by age group, and 12-month and 9-year prevalence proportions 
of PSA testing in Stockholm County, 2011 
Prevalence of PSA testing in Stockholm County, 2011 
Age group Population PSA in the last PSA in the last 
years n 12 months 9 years 
50‒59 121,260 16.5% 45.5% 
60‒69 103,344 26.9% 67.7% 
70‒79 50,266 30.5% 77.1% 
80‒89 22,546 23.4% 72.5% 
50‒89 297,416 23.0% 60.6% 
 
We addressed historical PSA testing by calculation of 1-, 2-, and 5-year prevalence 
over the period 2006‒2011. As illustrated for 1-year prevalence in Figure 6, it became 
increasingly common to come for PSA testing until 2009, after which testing decreased 
somewhat. 
 
Figure 5: One-year prevalence proportion of PSA testing for men in Stockholm, 2011. Red: Age groups 
uncommon to treat with curative intent (Age 80-89) or with low cancer incidence (Age 40-49). 
            
 
Frequent returns for second and third PSA tests can be seen as proxies for screening 
behavior. We found that almost half of the men over 50 years of age returned within 
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two years for a second test irrespective of the original PSA value. Strikingly, a third of 
these men will return within two years even if their first PSA value is below 1 ng/ml, 
which corresponds to a very low risk of long-term metastasis or death from prostate 
cancer [33,34]. Furthermore, of the men aged 80‒89 who would not gain from curative 
treatment of a prostate cancer, 52% came back for PSA testing within 2 years. We can 
illustrate this behavior by plotting the proportion of men without a second PSA test in 
men without previous prostate biopsy or prostate cancer diagnosis (Figure 6). 
 
 
Figure 6: Proportion of men not having a second PSA test. Survival function for time between first and 
second PSA test. Men with previous biopsy or PCa excluded. Red: Men with PSA < 1ng/ml. 
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5.2 PAPER II 
In 172 men with PSA levels of 1‒3 ng/ml who had not previously had a prostate biopsy 
or prostate cancer diagnosis, we found prostate cancer in 27% (n = 47).  Ten (6%) of 
the men had a tumor with a Gleason score of at least 7. After two years of follow-up, 14 
(8%) had had curative treatment (reviewed by me in August 2014). Median length of 
cancer lesion in men with prostate cancer was 2 mm (Table 11).  
 
Although the numbers were too small to evaluate statistically, they indicated a twofold 
risk of high-grade cancer in the high-risk group as compared to the population average 
(12% vs. 6%). 
 
Table 11: Results of first prostate biopsy in 172 men with PSA 1‒3 ng/ml selected according to genetic risk 
score category 
 Genetic risk score category  
 Low risk Intermediate risk High risk Total 
No. of participants 50 79 43 172 
Prostate cancer, % (n) 18 (9) 28 (22) 37 (16) 27 (47) 
Gleason 6, % (n) 16 (8) 22 (17) 26 (11) 21 (36) 
Gleason ≥ 7, % (n) 2 (1) 5 (4) 12 (5) 6 (10) 
 
 
Table 12 shows the logistic regression models where the genetic score was associated 
with the risk of prostate cancer (OR = 1.60). Small prostate volume was associated with 
an increased risk of prostate cancer, but the f/tPSA ratio was not. The cohort was 
selected according to tPSA and age, and as might be expected these variables were not 
significantly associated with outcome. 
 
Table 12: Logistic regression regarding risk of prostate cancer in 172 men aged 50‒69 years with PSA 
levels of 1‒3 ng/ml. Men with previous PCa were excluded. Family history was defined as any first -degree 
relative with PCa 
 Univariate Multivariate 
Risk factor OR CI (95%) p-value OR CI (95%) p-value 
Genetic score 1.67 1.11‒2.50 0.014* 1.60 1.05‒2.45 0.029* 
Total PSA, ng/ml 1.04 0.76‒1.40 0.83 1.06 0.72‒1.54 0.78 
Free PSA / total PSA 0.97 0.94‒1.01 0.16 0.98 0.95‒1.02 0.42 
Age, years 1.05 0.97‒1.14 0.21 1.08 0.99‒1.18 0.10 
Prostate volume, cm3 0.96 0.92‒0.99 0.013* 0.95 0.91‒0.99 0.010* 
Family history (yes/no) 0.60 0.25‒1.41 0.24 0.73 0.29‒1.81 0.49 
OR, odds ratio; CI, confidence interval. 
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Figure 7 illustrates the observed proportion (red bars) and calculated proportion (red 
line) of men with cancer findings according to their genetic score. The gray bars show 
the number of participants in each risk decile. 
 
Figure 7: Observed risk (red bars) and estimated risk (red line) of a positive biopsy in 172 men aged 50‒69 
years with PSA 1‒3 ng/ml, according to decile of genetic risk . Genetic risk was assessed by a genetic 
score based on SNP. Gray bars: sampling distribution of study subjects. 
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5.3 PAPER III 
Altogether, 531 participants (271 cases and 260 controls) with PSA levels of 3‒15 
ng/ml were included in the main analysis. Both PHI and the four-kallikrein panel 
showed higher AUC than the base model, both when predicting all prostate cancer and 
when predicting high-grade prostate cancer. However, as seen in Table 13, there was 
no significant difference in AUC between PHI and the four-kallikrein panel. 
 
Table 13: Performance of models predicting prostate cancer when applied to a cohort of 531 previously 
unbiopsied men with PSA 3‒15 ng/ml 
 All cancer High-grade cancer (Gleason 7+) 
Model 
AUC 95% CI 
  
p-value AUC 95% CI 
  
p-value 
  Base model 54.5 (49.6‒9.4) Ref. 59.6 (54.1‒65.8) Ref. 
  Four-kallikrein panel 69.0 (64.5‒73.4) < 0.01 71.8 (66.8‒76.7) < 0.01 
  PHI 70.4 (66.1‒74.8) < 0.01 71.1 (66.0‒76.2) < 0.01 
AUC comparison:  
PHI vs four-kallikrein panel 
  
0.52   0.77 
 
 
Compared to a strategy where the entire cohort is biopsied (as in clinical practice 
today), both PHI and the 4K model avoided biopsies. Using 4K model = 10% and PHI 
= 39 as the cutoff for biopsy, both models saved about a third of the biopsies at the cost 
of missing every tenth high-grade cancer, as illustrated in Table 14.  
 
Table 14: Head-to-head evaluation of the four-kallikrein panel (4K) and the PHI model in terms of saved 
biopsies and missed cancers compared to a strategy where the entire cohort is biopsied 
 Biopsies All cancers High-grade cancers 
Cutoff Performed Saved Missed Risk of cancer in 
unperformed biop. 
Missed Risk of high-grade cancer 
in unperformed biopsies 
 n % % % % % 
Biopsy all 1,000 0.0% 0.0% NA 0.0% NA 
4K       
   10% 704 29.6% 16.3% 28.0% 10.5% 9.5% 
   15% 550 45.0% 30.0% 34.0% 21.8% 12.9% 
   20% 437 56.3% 44.7% 40.5% 36.5% 17.2% 
PHI       
   26 915 8.5% 2.5% 15.3% 4.5% 14.1% 
   39 704 29.6% 15.1% 26.0% 9.8% 8.8% 
   47 550 45.0% 30.6% 34.7% 24.4% 14.4% 
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5.4 PAPER IV 
A total of 185,657 men without previous prostate cancer or prostate biopsy had their 
first PSA taken in Stockholm County during the period 2007‒2012 and were included 
in the study. The prevalence of low-dose aspirin, statin, and anti-diabetic medication 
was 12%, 12%, and 4%, respectively. Of these men, 18,574 were identified to have a 
first prostate biopsy after the PSA: 54% had benign biopsy findings, 17% and 23% had 
prostate cancer findings on biopsy with Gleason scores of ≤ 6 or ≥ 7, respectively. A 
comparison of PSA levels between users and non-users of the medications is given in 
Table 15.  
 
 
Table 15: Relationship between use of medications and PSA concentration in Swedish men undergoing 
their first PSA test and having no prior prostate cancer or prostate biopsy 
Medication % tPSA difference (users vs. non-users) 95% CI p-value 
Aspirin  −3.4% −5.2 to −1.7 < 0.001 
Statins −4.6% −6.2 to −2.9 < 0.001 
Metformin −15% −18 to −12 < 0.001 
Insulin −16% −19 to −13 < 0.001 
 
 
In multivariable regression analysis, increasing age, increasing PSA level, and 
decreasing f/tPSA were all associated with finding prostate cancer in general and high-
grade prostate cancer. Statin use was associated with an increased risk of any prostate 
cancer and high-grade prostate cancer (OR = 1.16 and 1.25; 95% CI: 1.04‒1.29 and 
1.10‒1.42). This effect persisted in subgroup analysis of both hydrophobic and 
hydrophilic statins. No significant association between prostate cancer and aspirin (OR 
= 1.1 and 1.03) or metformin (OR = 1.0 and 1.2) was seen―regarding any prostate 
cancer or regarding high-grade prostate cancer. 
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6 METHODOLOGICAL CONSIDERATIONS 
6.1 PAPER I 
Paper I was a descriptive, population-based study on the PSA testing behavior in 
Stockholm County. STHLM0 includes data on all PSA-tested men from all the three 
known laboratories in Stockholm County (Karolinska university Laboratories, Aleris, 
Unilabs), making conclusions at the population level possible. However, there is 
always the possibility that another laboratory in the area provides PSA tests. In search 
of PSA laboratories, we have repeatedly gathered information from both clinicians and 
laboratory personnel, but have found no evidence of other PSA laboratories in 
Stockholm County.  
 
Secondly, the study did not include data on men moving to Stockholm County after 
undergoing PSA testing outside the region, if they had no subsequent PSA test. 
Furthermore, there is a small chance that some Stockholm men get PSA-tested outside 
the region, e.g if living in the periphery of Stockholm. This proportion is difficult to 
estimate, but exclusion of the PSA tests on these men gives conservative estimates of 
the testing levels. Assuming that immigrant men had testing patterns similar to those of 
Stockholm men, we performed sensitivity calculations on the effect of migration and 
concluded that the underestimation of the 9-year testing prevalence was < 1.5%.  
 
Thirdly, Paper I does not provide any knowledge on why men or their physician decide 
to test while lacking information on the reason for testing. There are a number of 
situations where it is reasonable to test for PSA in older men or men with low PSA 
levels previously, e.g if there are symptoms suggestive of advanced disease. This study 
provides no means of differentiating these men from asymptomatic men coming for 
opportunistic screening. 
 
Finally, the study provides a description of the use of PSA tests in only one urban 
Swedish region with high opportunistic testing, and says less about national or 
international testing behavior. In the setting described, there is a certain amount of 
unnecessary testing. The test prevalence described is in line with previous studies on 
national PSA testing using cancer incidence as a proxy for PSA testing [135], 
increasing the validity of both studies. 
 
6.2 PAPER II 
Paper II was a prospective study investigating whether a genetic score gives predictive 
information about prostate biopsy results in men with low PSA values who are not 
biopsied in current clinical practice. It provides information on a group of men for 
whom evidence for level of performance of most biomarkers that have been suggested 
is lacking. Biopsying urologists and the single pathologist were blinded regarding the 
genetic score, reducing the risk of detection bias. However, the study had certain 
limitations. First and foremost, men were selected from the STHLM2 cohort, in which 
they were included when giving blood for a PSA test. Thus, the participants first had a 
PSA test for an unknown reason, then accepted being included in the STHLM2 cohort, 
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and finally agreed to undergo a prostate biopsy knowing that this would not have been 
done in clinical practice. It is likely that men with relatives with prostate cancer would 
be over-represented in such a selection process. Thus, the participants could hardly be 
expected to represent the general male population, possibly introducing selection bias. 
As family history was easily accessible, we incorporated this in the regression analysis, 
finding that the genetic score showed independent value besides the family history 
information. Apart from family history creating selection bias, there is no obvious 
reason why men in the study would differ from men in the Swedish population 
regarding the association between harboring SNPs (the genetic score) and prostate 
cancer. However, the association described must be interpreted with caution when 
dealing with international populations. 
 
Secondly, the study lacked power to analyze the association between genetic score and 
high-grade cancer, which is perhaps more interesting than the association with prostate 
cancer in general. The finding of 1, 4, and 5 high-grade cancers in the low, 
intermediate, and high genetic risk groups is interesting, but the numbers are too small 
for statistical analysis. Due to ethical considerations and limited resources, the study 
was powered to show differences in detection of overall cancer. Thus, the clinical 
implications of the findings remain unclear. The clinical benefit when comparing a base 
model with a model where the genetic score was added was roughly estimated using 
net reclassification improvement (NRI), which turned out to be positive but statistically 
insignificant. Larger studies are needed to address both the association between the 
genetic score and high-grade cancer, and the clinical usefulness of this score.  
 
 
6.3 PAPER III 
In Paper III, the performance of PHI and the four-kallikrein panel was evaluated in the 
STHLM2 cohort. The paper provides the first direct comparison of these two 
kallikrein-based models, showing strikingly similar performance. Together with most 
biomarker studies, our comparison lacked data on men with low PSA values. 
Furthermore, since all men were biopsied according to current clinical practice, use of 
the models will provide a means of saving some men from undergoing biopsy, but only 
at the cost of missing some cancers that would otherwise have been found in current 
practice (assuming that none of the models are “perfect”). However, there is no obvious 
reason why the similarities in performance would change drastically in men with low 
PSA, making it possible that the four-kallikrein panel and PHI would perform similarly 
in general. The actual performance of these models in men with low PSA is, however, 
still not known. 
 
Neither DRE, prostate volume, nor family history were available. As these are often 
considered in clinical biopsy decisions, this may have introduced selection bias into the 
study, adding to the possible selection bias due to inclusion into the STHLM2 cohort 
mentioned above. However, the participants were all men in Stockholm County being 
biopsied in clinical practice after inclusion in STHLM2, making it a relevant cohort of 
men to explore. 
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Finally, f/tPSA is in clinical use in Sweden, making use of biomarker panels 
incorporating this performing relatively less well in a Swedish cohort. That is, some of 
the biopsies were probably decided upon using f/t PSA information. It could then be 
expected that the models explored would perform less well than in a setting where only 
tPSA is used. 
 
6.4 PAPER IV 
Paper IV was a retrospective, population-based study exploring the association between 
use of three pharmaceutical drugs on the one hand and PSA levels and the risk of 
finding prostate cancer from biopsy on the other. There are apparent risks of bias in all 
observational studies, and this study had several limitations. Firstly, we lacked 
information on the indication for PSA testing in men in Stockholm, giving a risk of 
selection bias. However, two-thirds of men aged > 50 years undergo PSA testing in this 
region (Paper I). This suggests that the difference in testing between men on aspirin, for 
example, and men without medication could be limited. To investigate the possible 
effect of this on PSA level estimations, we adjusted the linear regression for both age 
and comorbidity, including only the first known PSA test in each man.  
 
Secondly, it is possible that men on medication seek biopsy more or less often than 
others. With this, there is a risk of introducing detection bias that masks potential 
protective effects of the medication. If so, it could follow that we would find more 
insignificant cancer in men on medication if they are biopsied more frequently. To 
address this, we only included men coming for their first biopsy, and our logistic 
regression model included both age, comorbidity, education, PSA levels, and use of 
medications.  
 
Thirdly, there was a risk of exposure misclassification as we lacked data on 
medications bought over the counter. Since non-prescription use will probably continue 
also in a setting with organized chemoprevention, we believe that the situation reflected 
is relevant. 
 
Finally, as in other observational studies, residual confounding may have been 
introduced by unmeasured risk factors for prostate cancer (e.g. physical activity, diet, 
and body mass index). In summary, our study shares apparent risks of bias and residual 
confounding with previous observational studies on the subject, which possibly 
explains the wide-ranging estimates of the associations between these drugs and 
prostate cancer.  
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7 DISCUSSION 
7.1 PSA TESTING BEHAVIOR 
7.1.1 PSA testing in men aged 50‒69 years 
In Paper I, we found that PSA testing and retesting in Stockholm County, where PSA 
screening is not recommended, was common in all men aged over 50 years and that it 
was uncommon in younger men. How one should appraise this depends very much on 
the age and PSA level of the men being tested. Men aged below 70 have the clearest 
benefit from treatment with radical prostatectomy for prostate cancer, and the ages 50‒
69 years are often suggested to be relevant for prostate cancer screening [136]. We 
showed that 46‒67% of men in this age group had had a PSA test during the previous 9 
years and that 25‒40% had had a PSA test during the previous two years. When 
addressing retesting, we note that half of all men in this age group return for another 
PSA test within three years, even if they have had an original PSA value below the 
traditional threshold for prostate biopsy (3 ng/ml). The intensity of PSA testing in 
Stockholm County is almost comparable to participation rates in the screening arm of 
the ERSPC screening trial (82%), but without the positive attributes of an organized 
screening program [90]. With this in mind, it is reasonable to state that there is 
frequent, unorganized testing in Stockholm County in men who are relevant to 
organized prostate cancer testing programs.  
 
 
7.1.2 PSA testing in elderly men 
One of the suggested golden rules for prostate cancer screening is: “Don’t screen men 
who won’t benefit” [98]. No guidelines support early detection of prostate cancer with 
PSA in men over 75 years old, and indeed there is no mortality-related benefit of 
treating men much over 70 years curatively for prostate cancer [136,137]. It has been 
estimated that almost half of all prostate cancers detected in screening programs 
represent over-detection [138]. Screening for localized prostate cancer in men over 70 
years of age could result in even higher proportions, giving a high risk of unnecessary 
treatment.  
 
Limited use of PSA testing does serve a role in elderly men with symptoms or 
palpatory findings on rectal examination suggestive of advanced prostate cancer. These 
men are, however, few―especially when compared with the number of men with 
benign voiding symptoms. Approximately 20% of men aged > 75 years have lower 
urinary tract symptoms (LUTS) or a diagnosis of benign prostatic hyperplasia (BPH) 
[139]. Although EAU states that PSA measurement should be performed only if a 
diagnosis of prostate cancer will change the management of BPH [140], such 
symptoms possibly drive PSA testing.  
 
We found that in all age groups, PSA testing is most common in men aged 70‒79 and 
80‒89 years where two out of three men have had their PSA taken in the last five years 
(in both cases). Even more illustrative is the fact that every fourth man aged 80‒89 
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years has had his PSA taken in the last 12 months. This means that 31% (27,551 out of 
89,209) of men aged 40‒89 years who were tested in Stockholm County in 2011 were 
over 70 years of age, illustrating that unnecessary and probably harmful testing is 
common. 
 
Moreover, as PSA testing is not organized centrally, PSA testing rates can vary 
between doctors. In a US setting, a 10-fold difference in PSA testing rates in men aged 
more than 75 years has been shown between the 10% of primary care physicians testing 
most and least often [141]. The high and variable level of PSA testing in elderly men 
calls for organized testing or improvement in guidelines. 
 
 
7.1.3 Retesting in men with low baseline PSA level 
With regard to studies on the low long-term risk of prostate cancer metastasis and death 
in men with low baseline PSA in mid-life, it is relevant to focus also on retesting habits 
in men with low PSA levels [33,34,97]. EAU guidelines have used this knowledge, 
recommending a retest interval of 8 years if baseline PSA is < 1 ng/ml [4]. In this light, 
it is remarkable that every third man in Stockholm County with PSA< 1 ng/ml has a 
second PSA test within 2 years. On the other hand, approximately 30% and 10% of 
men with PSA< 1 ng/ml and 4‒10 ng/ml respectively have not returned for subsequent 
PSA testing within 6 years, indicating that there probably still is a proportion of men 
without reasonable follow-up. This frequent retesting behavior is pronounced in all age 
groups over 60 years, with lower frequency of retesting in younger men. 
 
Frequent testing in elderly men and men with low baseline PSA drive over-diagnosis of 
cancers that would not affect the man if untreated, and over-treatment where men are 
subjected to treatment that does not prolong their life but has negative effects on quality 
of life [96]. Furthermore, there is an unknown health-economic cost related to this 
unnecessary testing. Our findings contrast with recent knowledge and existing 
guidelines, and may have a profound impact on the organization of future prostate 
cancer testing. 
 
 
Table 16: Findings in Paper I that contrast with current guidelines. Study population: men in Stockholm 
County without a diagnosis of prostate cancer. 
Age 
group, 
years 
PSA level, 
ng/ml 
Test prevalence, 
% 
Cumulative incidence of second PSA 
test within 26 months, % 
70‒79 all 67.9 (last 5 years) 57.5 
80‒89 all 72.5 (last 9 years) 52.8 
40‒89 < 1 N.A. 33.7 
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7.2 UNDETECTED PROSTATE CANCER IN MEN WITH LOW PSA 
A major drawback of most biomarker studies for detection of prostate cancer is that all 
men undergoing biopsy in most studies are chosen due to their elevated PSA, although 
every fourth man with PSA 1‒4 ng/ml has prostate cancer and 2‒7% of them have 
prostate cancer of Gleason grade ≥ 7[32].  
 
Using data from STHLM0 and Paper I (see section 4.1), we can calculate the number of 
men aged 60‒69 in Stockholm County by PSA strata (proportion of PSA-tested men 
within stratum times the size of the male population). Assuming that the proportions of 
prostate cancer are consistent between the Swedish and the predominantly white US 
population used in the PCPT trial, we can then estimate the number of Stockholm men 
aged 60‒69 years with undetected prostate cancer by PSA stratum, as shown in Table 
17. The validity of this assumption is supported by findings in Paper II (6% Gleason ≥ 
7 tumors in men with PSA 1‒3 ng/ml). 
 
Table 17: Estimated number of men aged 60‒69 years in Stockholm County that harbor prostate cancer. 
High-grade prostate cancer was defined as Gleason score ≥ 7 
STHLM0 data  Data from Thompson et 
al. [32] 
 
PSA,  
ng/ml 
Est. men in 
population, 
n 
 Men with 
PCa,  
% 
Men with 
high-grade 
PCa, % 
Est. men with 
PCa, 
n 
Est. men with 
high-grade 
PCa, 
n 
1.1‒2.0  28,461  17% 2.0% 4,838 571 
2.1‒3.0 13,238  24% 4.7% 3,164  626 
3.1‒4.0 7,472  27% 6.7% 2,010 502 
All psa 103344     
PCa, prostate cancer; Est., Estimated. 
 
 
From Table 17, it follows that approximately 1% ([571+626]/103,344) of all men in 
Stockholm aged 60‒69 years would be diagnosed with high-grade prostate cancer if 
biopsied, though having a PSA below a commonly used threshold for biopsy (3 ng/ml). 
These men are under-diagnosed today and are at risk of developing advanced disease.  
 
Furthermore, while there are more men with PSA levels of 2‒3ng/ml than men with 3‒
4 ng/ml, in absolute terms there are approximately 20% (626 vs. 502) more men in the 
lower range who have high-grade tumors than in the higher range―even though the 
risk of cancer is higher with increasing PSA. 
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7.3 PERFORMANCE OF BIOMARKER MODELS 
7.3.1 Detection of prostate cancer in men with low PSA 
In order to reduce over-diagnosis, over-treatment, and biopsy-related morbidity, it is of 
utmost importance to reduce the number of biopsies performed. Only this would 
effectively reduce the number of insignificant tumors detected and the number of post-
biopsy infections due to antibiotic-resistant bacteria. 
 
Virtually all studies of suggested biomarkers in prostate cancer use samples from 
cohorts of men who have undergone prostate biopsy based on their age and tPSA level. 
These studies can therefore only lead to conclusions regarding settings in which men 
are first chosen on the basis of PSA level and age, and only thereafter is the new tool 
applied. In this context, a new biomarker can only save biopsies at a certain cost 
(missed cancers) while all men would be biopsied in current practice (they were all 
chosen based on PSA level) and no suggested biomarker has yet been perfect (perfectly 
identifying only men with cancer). 
 
One solution to detection of as many high-grade cancers as today or more, and still be 
able to decrease the number of biopsies is to find men with a high risk of prostate 
cancer among men who are not biopsied today. This can be done either through (1) 
better organized testing in order to find men who are not tested at all in current practice 
or (2) also testing for prostate cancer in men with low PSA in order to detect the high-
grade cancers described above (section 7.2). 
 
 
7.3.2 Genetic score 
With genotyping being increasingly available and cheap, this opens up a way of 
estimating an individual’s risk of prostate cancer originating from genetic factors. 
Single-nucleotide polymorphisms (SNPs) now have the advantages of being cheap, 
stable (need only to be measured once), and easy to analyze. The individual increase in 
risk if carrying an individual nucleotide polymorphism is low, but the 100 nucleotide 
polymorphisms known to be associated with prostate cancer explain about a third of all 
familial risk [70,142,143]. Previously, the STHLM1 study used a genetic score based 
on the then validated 35 SNPs, indicating that roughly every fourth biopsy procedure 
could be avoided at the cost of missing 8% of cancers of Gleason score ≥ 7 [72]―if the 
genetic score was applied to men biopsied according to current clinical practice. A 
calculation was also performed estimating that the proportion of saved biopsies could 
increase to every third biopsy if all SNPs associated with prostate cancer were known. 
 
We performed the study in Paper II in order to determine whether the genetic score was 
also informative regarding the risk of cancer in men with low PSA, thereby giving the 
possibility of identifying men with prostate cancer not detected in today’s routines. In 
172 previously unbiopsied men aged 50‒69 years with a PSA level of 1‒3ng/ml, we 
found that 27% and 6% harbored prostate cancer and high-grade prostate cancer 
(Gleason score ≥ 7) respectively.  
We found an increased risk of prostate cancer with increasing genetic score (OR = 
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1.60; 95% CI: 1.05‒2.45) with an absolute increase in risk of 10 percentage points 
(37% vs. 27%) for men in the highest genetic risk decile, as compared to the population 
average. The Gleason ≥	 7 tumors were distributed as 2%, 5%, and 12% in the low-, 
intermediate-, and high-risk groups, respectively. This might indicate a twofold 
increase in risk (12% vs. 6%) in men in the high-risk group compared to the 
population average, but the numbers are too small for proper statistical evaluation. 
The adjusted association between the genetic score and risk of prostate cancer was 
similar in this study to that in a previous study on men with higher PSA (OR = 1.60 vs. 
1.52), possibly indicating that the genetic score performs equally well in all PSA strata. 
Though providing independent information, the modest increase in AUC when 
comparing previously published genetic score models with clinical models based on 
currently available variables (age, family history, tPSA, f/tPSA, prostate volume) might 
indicate that the optimal biomarker panel for predicting risk of prostate cancer should 
also incorporate additional variables. 
 
 
7.3.3 PHI and the four-kallikrein panel/4Kscore 
Both the Prostate Health Index (PHI) and the four-kallikrein panel (4Kscore) represent 
multiplex protein biomarker models predicting the risk of prostate cancer in terms of an 
index (PHI) or percentage risk of outcome (4Kscore). PHI is a commercially available, 
FDA-approved test (Beckman Coulter Inc.) and the 4K panel is commercially available 
(4Kscore; OPKO Health Inc.), but is not FDA-approved. Instead, it is offered as a 
laboratory-developed test (LDT).  
 
Both tests were developed to aid biopsy decisions and they have been validated 
separately in men undergoing biopsy in current practice, thus having at least 
moderately increased PSA. In men coming for first biopsy, both models have 
repeatedly shown an independent additional value when added to current clinically 
available information (age, prostate volume/DRE, tPSA, f/tPSA). The individually used 
risk cutoff could be chosen according to patient/doctor preference, and the clinical 
usefulness of avoiding biopsies is dependent on the cutoff chosen for biopsy. PHI = 27 
is a suggested cutoff for PHI and a 20% risk of high-grade cancer is often used to 
illustrated 4Kscore performance. Using the 4Kscore, a third to half of all biopsies can 
be avoided at the cost of missing every tenth to twentieth high-grade cancer. For PHI, it 
has been reported that 15% of biopsies can be avoided at to the cost of missing only a 
few percent of high-grade cancers. Thus, the use of PSA derivatives and additional 
kallikrein markers has the potential to improve the current performance characteristics 
of the PSA test alone [144]. However, there has been a lack of comparisons between 
these two tests with apparently similar characteristics. 
 
We used a population-based cohort of 531 men with PSA 3‒15 ng/ml and prostate 
cancer or benign findings on a first prostate biopsy to provide an external validation 
and head-to-head comparison between PHI and the four-kallikrein panel (4Kscore). 
Both tests independently improved discrimination for both prostate cancer and high-
grade disease compared to a base model, and there was no significant difference in 
discrimination between the tests. Since a prostate cancer test must have high sensitivity, 
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we also compared partial AUC when sensitivity exceeded 75%. In this analysis also, 
there was no significant difference in discrimination between the two models.  
 
The finding that PHI and the four-kallikrein panel performed comparably well in 
predicting all prostate cancer and high-grade prostate cancer is further reflected in the 
analysis of potentially saved biopsies. In order to avoid 30% of biopsies, a cutoff of 
10% for the four-kallikrein panel and PHI = 39 was determined. When using these 
cutoffs, 10.5% and 9.8% of high-grade cancers, respectively, were missed. 
 
In this dataset, previously suggested phi cutoffs (25‒30) corresponded to a low risk of 
prostate cancer and PHI in the range 30‒40 had better properties. This was also 
reflected in calibration curves where PHI was poorly calibrated to previously reported 
associations between prostate cancer risk and PHI level. The four-kallikrein panel was 
well calibrated, both for predicting high-grade prostate cancer and all prostate cancer. 
 
In summary, PHI and the four-kallikrein panel performed similarly, with small 
discrepancies in calibration characteristics. As both biomarker models contain 
measurements of biologically closely related kallikreins, this finding may not be 
surprising. Sensitivity analyses including men with higher PSA and previous biopsy did 
not alter the results materially. From a clinical point of view, this is reassuring, since 
previous biopsy status may not always be known―and since the models are also of 
potential value for deciding on prostate biopsy in men with PSA levels outside the 3–15 
ng/ml range.  
 
 
7.4 CHEMOPREVENTION OF PROSTATE CANCER 
Because no other study design can provide the safeguards against bias associated with 
randomization, randomized controlled trials (RCTs) are essential to provide a basis for 
recommendations on prevention of cancer. The inability of observational studies to 
control for unknown prognostic factors leads to a risk of biased conclusions. Therefore, 
observational studies are classified as providing weaker evidence than RCTs [145]. 
However, RCTs consume vast amounts of resources and other study designs can be 
used to determine whether to initiate a trial.  
 
An example of discripancies between results of observational studies and randomized 
trials is the controversy surrounding postmenopausal hormonal replacement therapy 
(HRT). Numerous observational studies had appeared that indicated that HRT was 
“good for you”, which is why a very large randomized trial (Women’s Health 
Initiative; WHI) was initiated. WHI recruited 16,608 post-menopausal women that 
were randomized to combined estrogen/progesterone-treatment or placebo. 
Surprisingly, this indicated that a combined regimen of estrogen and progesterone 
increases the risk not only of breast cancer (HR 1,26) but also of cardiovascular disease 
(HR 1.22), and the trial was stopped after five years due to the association between 
breast-cancer and HRT[146,147].  
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Pharmaceutical drugs already in common use are interesting and feasible to explore for 
chemoprevention, for a number of reasons. Firstly, the security profile is already known 
and rare side effects are also hopefully reported. Secondly, generic medications or at 
least cost-effective alternatives might be available. Finally, assuming that the condition 
the drug is in current use for is not associated with the development of cancer, the 
association of medication with cancer risk can be explored through observational 
studies, often using existing data from registries or previous studies on other subjects. 
 
Aspirin and statins are widely used for prevention of cardiovascular disease, have a 
relatively benign security profile, and are cost-effective. A number of observational 
studies have found associations between aspirin, statin, and metformin use and the risk 
of prostate cancer (see section 1.5). A modest inverse association between the risk of 
prostate cancer and aspirin or statins has been reported, but the evidence is conflicting. 
Furthermore, there is no clear dose-response effect. Metformin is a potent anti-diabetic 
medication with somewhat more side effects, but even so, RCTs have been suggested 
based on findings in some retrospective studies [148]. 
 
As we are well aware that point estimates of observational studies have, historically, 
differed substantially from those of subsequent trials, RCT initiatives on aspirin, statins, 
or metformin are mandatory if considering prevention of prostate cancer with those 
drugs. In order to decide on whether to support such initiatives, we used a Swedish 
population-based cohort to provide additional retrospective evidence on the association 
between aspirin, statins, or metformin and the risk of prostate cancer. When including 
socioeconomic data, comorbidity data, PSA levels, and clinical data, we found no 
inverse association between these medications and the risk of finding cancer or high-
grade cancer on biopsy; on the contrary, we found an increased risk of cancer in men 
on statin therapy. 
 
In line with previous studies, we found slightly lower PSA levels in men on aspirin, 
statin, or anti-diabetic medication, which would possibly affect the results of 
observational studies without access to PSA data.  
 
The population-based nature of the STHLM0 cohort, the independent ascertainment of 
exposure data, and access to original PSA and biopsy data gave strength to the study. In 
summary, we found no support for initiation of a trial on the relationship between these 
drugs and the risk of prostate cancer. As further discussed in the methodological 
considerations (section 7.5), we acknowledge the risk of several kinds of bias and 
confounding associated with observational studies. 
 
 
7.5 FUTURE PERSPECTIVES 
7.5.1 Organized prostate cancer testing 
A large proportion of Swedish men undergo testing for prostate cancer, as illustrated in 
Paper I. The same has previously been shown in other nationalities to varying degrees 
[149-151]. While this unorganized screening behavior is present, I agree with the 
Editorial on Paper I, stating that “screening for prostate cancer is likely here to stay” 
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[152]. Also, the majority of authors in the recent Lancet Oncology review on early 
detection of prostate cancer stated that “PSA screening does reduce death from 
prostate cancer” [153]. This is supported by the findings in the ERSPC trial, showing a 
substantial reduction in prostate cancer mortality in men in the PSA screening group. In 
this trial, the number needed to invite (NNI) to prevent one death from prostate cancer 
was roughly 800, being substantially lower than commonly reported NNIs for breast 
cancer screening (NNI 1339-2000) [90]. From this, it is not reasonable to believe in 
implementing a complete stop in prostate cancer testing in asymptomatic men. 
However, as discussed in section 2.4, this is a matter of debate―where both USPTF 
and the Canadian CTFPHC recommend against screening with PSA because of the 
high degree of over-diagnosis and common side effects of diagnosis and treatment 
(biopsy complications, postoperative incontinence/impotence, post-radiation 
incontinence/bowel dysfunction/impotence) [100,101]. 
We have shown how the unorganized testing situation in Sweden drives testing in men 
who do not benefit from it due to age or PSA level. Organized testing programs are a 
way of reducing test-related harm―such as over-diagnosis and over-treatment―in 
these men. An often overlooked feature of the screening debate has been that screening 
trials only study testing within the study population (e.g. men aged 50‒69 years). If 
implementing an organized program and thereby also controlling testing outside the age 
range relevant to screening, test-related harm outside this age range could be reduced 
(e.g. in elderly men). 
 
The goal of a testing program is, however, not necessarily a 100% participation rate. 
Rather, the objective of an organized prostate cancer testing program should be to (1) 
invite men who will potentially benefit from testing, aiming to include only well-
informed and willing men, and (2) avoid testing in men who would not benefit from it. 
 
 
7.5.2 Validation of suggested biomarkers 
In order to detect as many high-grade cancers with a risk-assessment tool as when using 
a cutoff for biopsy based only on age and PSA, men with lower PSA than this cutoff 
must be biopsied. For this, new biomarkers must be validated in study populations 
including men with low PSA. With this, it follows that new screening trials, where men 
are not selected merely based on levels of PSA in the experimental arm, will be needed.  
 
The STHLM3 trial (www.sthlm3.se) addresses the 
question of whether a biomarker panel based on age, 
family history, biopsy history, protein levels (kallikreins, 
beta-microseminoprotein, growth differentiation factor 15 
etc.), and genetic information (single-nucleotide 
polymorphisms) can save prostate biopsies while 
maintaining the sensitivity for high-grade disease. It is 
currently being performed in Stockholm and uses a paired 
design where men aged 50‒69 years with a high risk of 
prostate cancer (as judged by a PSA cutoff of 3 ng/ml or the biomarker panel) are 
invited for prostate biopsy (See Figure 9, Red). Included men with a normal or low risk 
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of prostate cancer are recommended retesting in line with current knowledge. The 
STHLM3 trial has included more than 55,000 men (November 2014), and will publish 
preliminary results in March 2015. 
 
The STHLM3 trial introduces prostate biopsy in men who do not come for biopsy in 
current practice. Thus it explores the idea of finding more cancers in men with low PSA 
in order to maintain sensitivity for high-grade tumors while avoiding biopsies in men 
with moderately increased PSA. Adequate validation of future additional biomarkers 
should ideally relate to this concept.  
 
Figure 8: The design of the STHLM3 trial. 
 
 
 
 
7.5.3 A new diagnostic pipeline for prostate cancer 
Today, the situation in prostate cancer diagnostics is marked by frequent, unorganized 
testing with an inadequately performing biomarker (PSA). For men with increased 
PSA, this is followed by systematic (and not targeted) biopsy― finding (at least to 
some degree) insignificant tumors and causing increased infectious complications. 
Treatment decisions are then often based on biopsy findings in terms of Gleason score 
and extent of spread together with findings on MRI. 
 
In order to enhance the performance of the diagnostic pipeline for prostate cancer, a 
number of measures can be taken. One possible direction forward could be 
accompanied by studies at several levels, as outlined in Figure 9. Firstly, an improved 
blood test used in men who would benefit from testing must be established. This would 
need both validation studies of existing biomarkers―as discussed above, especially in 
men not undergoing prostate biopsy in today’s practice―and development of new 
biomarkers to be validated later (S1). Furthermore, testing behavior in men needs to be 
clarified further, e.g. by addressing current PSA testing habits in men according to 
socioeconomic factors and comorbidity (S2). 
 
Men in Stockholm 
aged 50-69 
Low risk of prostate cancer 
Testing is recommended in 6-10 years 
Best Possible 
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PSA<1 
Normal risk of prostate cancer 
Testing is recommended in 2-4 years 
Increased risk of prostate cancer 
Biopsy is recommended 
PSA≥1 
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• MIC-1 
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•  256 SNPs 
•  Plasma biomarkers 
•  Clinical data 
STHLM3 Design 
PSA<1 
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PSA≥3 and/or 
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Yellow 
Red 
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Secondly, for men being treated for prostate cancer, it is already increasingly common 
to undergo MRI. Current evidence indicates that MRI-targeted biopsies - either 
directing the biopsy needle through fusion with ultrasound or direct in the MRI tube -
can reduce the number of insignificant tumors and the number of performed biopsies 
while increasing the numbers of detected significant tumors [88]. With this follows 
reduced morbidity due to the infectious complications of prostate biopsies. However, 
the concept of performing MRI before biopsy to target the tumor needs to be validated, 
both in men coming for initial biopsy and in those coming for re-biopsy (S4). The 
continuously evolving performance of modern MRI done before targeted biopsies in 
guiding definitive treatment also needs further validation (S3). Meanwhile, it is of 
utmost importance that current biopsy practice should be updated in line with the 
increasing numbers of infectious complications with antibiotic-resistant bacteria. 
Continuous improvement of biopsy technique is warranted and might include both 
cross-sectional studies on current practice and randomized studies on individual 
suggested improvements such as disinfected biopsy needles [154] (S5). 
 
Finally, genomic profiling with next-generation sequencing tools on biopsy and 
surgical specimens is rapidly developing due to technological advances. Additional 
features complementing the Gleason score to help tumor grading are evolving, and with 
existing surgical specimens of high quality together with long follow-up time, the 
validation and implementation of such tools need not to be far away (S6). 
 
 
Figure 9: A new diagnostic pipeline for prostate cancer and suggested studies.  
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